60. Aplastic anemia
[
184 clinical trials,
212 drugs（DrugBank:
61 drugs),
35 target genes / 136 target pathways ]
Searched query = "Aplastic anemia"
The queries were searched in Public_title, Scientific_title, and Condition of the data. Export date: 11/21/2019, 11/20/2019. Trials are sorted by Date_enrolment from most recent to oldest in the table.
| No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT03988608 | December 9, 2019 | 28 October 2019 | Study to Assess the Safety and Efficacy of Eltrombopag in Chinese Refractory or Relapsed Severe Aplastic Anemia (SAA) Subjects. | A Non-randomized, Open-label, Multi-center, Phase II Study to Assess the Safety and Efficacy of Eltrombopag in Chinese Subjects With Refractory or Relapsed Severe Aplastic Anemia | Aplastic Anemia | Drug: Eltrombopag 25 mg | Novartis Pharmaceuticals | Not recruiting | 18 Years | N/A | All | 20 | Phase 2 | ||
| 2 | JPRN-JapicCTI-194962 | 21/10/2019 | 7 October 2019 | A Phase 2/3 Study of AMG531 in Patients with Aplastic Anemia | A Phase 2/3 Study of AMG531 Combined with Ciclosporin A in Patients with Aplastic Anemia Previously Untreated with Immunosuppressive Therapy | Aplastic Anemia | Intervention name : AMG531 INN of the intervention : romiplostim Dosage And administration of the intervention : SC-administered Control intervention name : - INN of the control intervention : - Dosage And administration of the control intervention : - | Kyowa Kirin Co., Ltd | Not Recruiting | 20 | BOTH | 24 | Phase 2-3 | Japan, Asia except Japan | ||
| 3 | JPRN-jRCTs071190032 | 21/10/2019 | 5 November 2019 | W-JHS AA02 | Investigation on the effectiveness of rabbit ATG + cyclosporine + eltrombopag therapy for patients with aplastic anemia - W-JHS AA02 | aplastic anemia | 1. The administration of rATG; 2.5 mg/kg, iv. daily, day 1 - day 5 + CsA; 5 mg/kg, po. bid (before breakfast and before dinner) +adrenalcorticosteroid (the dose is mentioned after) is started. CsA used is Neoral or generic drug emulsified in the same way with Neoral. A blood level of CsA is measured and the dose which CsA blood level 2 hours after oral administration (C2) reachs 600 - 900 ng/mL is adjusted. The investigator shall reduce the dose of CsA by 25% on this occasion when blood trough level (C0) just before the administration is beyond 250 ng/mL because renal function disorder may occur (2). When serum creatinine level also becomes higher than 150% of baselines, the 25% dose reduction of CsA shall be performed. If C2 did not reach to 600 ng/mL, then dose of CsA is appropriately increased. 2. EPAG; 75 mg, po. daily (before sleep, requires to pass more than at least 2 hours after dinner) is started from day 6. 3. The dose of steroid is as follows: Day 1 - day 5: methylprednisolone 2 mg/kg/day Day 6: Methylprednisolone 1 mg/kg/day Day 8, 10, 12, 14, 16, 18, 20: prednisolone 0.5 mg/kg/day Discontinuation after day 21 4. The administration of CsA and EPAG is continued for 26 weeks. When it passed 26 weeks, further treatment mentioned above is entrusted to the investigator in each medical institution after 27 weeks if patients reached Camitta criteria CR or PR. However, the administration is continued for 52 weeks even if the dose of CsA is reduced. The treatment after 53 weeks is not specified. If patients did not reach CR or PR at 26 weeks, treatment after 27 weeks is entrusted to the investigator in each medical institution (it is not specified in this study). | Shinji Nakao | Recruiting | >= 18age old | < 80age old | Both | 60 | Phase 2 | none | |
| 4 | NCT03836690 | October 21, 2019 | 4 November 2019 | Transfer of Effector Memory T Cells (Tem) Following Allogeneic Stem Cell Transplantation | Phase I Study of Transfer of Effector Memory T Cells (Tem) Following Allogeneic Stem Cell Transplantation | Lymphoma;Leukemia;Myeloma;Myelodysplastic Syndromes;Severe Aplastic Anemia;Primary Immune Deficiency;Graft Vs Host Disease | Biological: CD62L- Tem | University College, London | Medical Research Council | Recruiting | 16 Years | 70 Years | All | 18 | Phase 1 | United Kingdom |
| 5 | NCT04099966 | October 1, 2019 | 7 October 2019 | AlloSCT for Malignant and Non-malignant Hematologic Diseases Utilizing Alpha/Beta T Cell and CD19+ B Cell Depletion | Allogeneic Stem Cell Transplantation for Malignant and Non-malignant Hematologic Diseases Utilizing Alpha/Beta T Cell and CD19+ B Cell Depletion - NYMC 588 | Acute Leukemia;Severe Aplastic Anemia;Non-hodgkin Lymphoma;Hodgkin Lymphoma;Kostmann;Diamond Blackfan Anemia;Amegakaryocytic Thrombocytopenia;Sickle Cell Disease;Beta-Thalassemia | Drug: alpha beta depletion | Mitchell Cairo | Not recruiting | N/A | 30 Years | All | 20 | Phase 2 | United States | |
| No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
| 6 | NCT04095936 | October 2019 | 28 October 2019 | Study of AMG531 (Romiplostim) in Patients With Aplastic Anemia | A Phase 2/3 Study of AMG531 Combined With Ciclosporin A in Patients With Aplastic Anemia Previously Untreated With Immunosuppressive Therapy | Aplastic Anemia | Drug: Romiplostim | Kyowa Kirin Co., Ltd. | Not recruiting | 20 Years | N/A | All | 24 | Phase 2/Phase 3 | ||
| 7 | ChiCTR1900026462 | 2019-08-19 | 14 October 2019 | Clinical study for umbilical cord blood mesenchymal stem cells combined with peripheral blood stem cells co-transplantation with reduced PT-Cy in the prevention of GVHD in the treatment of aplastic anemia | Clinical study for umbilical cord blood mesenchymal stem cells combined with peripheral blood stem cell co-transplantation with reduced PT-Cy in the prevention of GVHD in the treatment of aplastic anemia--single-center, single-arm, open clinical study | aplastic anemia,AA | Cass series:low dose post Cyclophosphamide and Mesenchymal stem cell; | Cancer Hospital Affiliated to Zhengzhou University-He'nan Cancer Hospital | Recruiting | Both | Cass series:20; | Phase 0 | China | |||
| 8 | NCT03622788 | August 8, 2019 | 14 October 2019 | Cytokine-Treated Veto Cells in Treating Patients With Hematologic Malignancies Following Stem Cell Transplant | Anti-Viral Central Memory CD8 Veto Cells in Haploidentical Hematopoietic Stem Cell Transplantation | Acute Lymphoblastic Leukemia;Acute Myeloid Leukemia;Aplastic Anemia;Bone Marrow Failure;Chronic Lymphocytic Leukemia;Chronic Myelogenous Leukemia, BCR-ABL1 Positive;Donor;Follicular Lymphoma;Hematopoietic Cell Transplant Recipient;Hodgkin Lymphoma;Mantle Cell Lymphoma;Myelodysplastic Syndrome;Myeloproliferative Neoplasm;Non-Hodgkin Lymphoma;Plasma Cell Myeloma | Biological: Anti-Thymocyte Globulin;Drug: Cyclophosphamide;Biological: Cytokine-treated Veto Cells;Drug: Fludarabine;Procedure: Peripheral Blood Stem Cell Transplantation;Radiation: Total-Body Irradiation | M.D. Anderson Cancer Center | National Cancer Institute (NCI) | Recruiting | 12 Years | 70 Years | All | 24 | Phase 1/Phase 2 | United States |
| 9 | NCT03896971 | May 15, 2019 | 24 June 2019 | Combination of Thrombopoietin Mimetic and Immunosuppressive Therapy in Aplastic Anaemia | Treatment With Thrombopoietin Mimetic Plus Immunosuppressive Therapy in Egyptian Patients With Aplastic Anaemia | Aplastic Anemia | Drug: Combination of thrombopoietin mimetic and cyclosporin A | Safaa AA Khaled | Assiut University | Recruiting | 16 Years | 65 Years | All | 60 | Phase 4 | Egypt |
| 10 | NCT03957694 | April 25, 2019 | 28 October 2019 | Study of AMG531(Romiplostim) in Patients With Aplastic Anemia | A Phase 2/3 Study of AMG531 in Patients With Aplastic Anemia PreviouslyUntreated With Immunosuppressive Therapy | Aplastic Anemia | Drug: Romiplostim | Kyowa Kirin Co., Ltd. | Recruiting | 20 Years | N/A | All | 14 | Phase 2/Phase 3 | Japan | |
| No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
| 11 | JPRN-JapicCTI-194746 | 01/2/2019 | 16 July 2019 | A Phase 2/3 Study of AMG531 in Patients with Aplastic Anemia | A Phase 2/3 Study of AMG531 in Patients with Aplastic Anemia Previously Untreated with Immunosuppressive Therapy | Aplastic Anemia | Intervention name : AMG531 INN of the intervention : romiplostim Dosage And administration of the intervention : SC-administered Control intervention name : - INN of the control intervention : - Dosage And administration of the control intervention : - | Kyowa Hakko Kirin Co., Ltd | Not Recruiting | 20 | BOTH | 14 | Phase 2-3 | Japan, Asia except Japan | ||
| 12 | NCT03825744 | February 2019 | 25 February 2019 | Hetrombopag or Placebo in Treatment-Naive Severe Aplastic Anemia | A Phase III Multicenter Randomized Study of Hetrombopag or Placebo in Treatment-Naive Severe Aplastic Anemia | Severe Aplastic Anemia | Drug: Hetrombopag Olamine+Standard Therapy;Drug: Placebo+Standard Therapy | Jiangsu HengRui Medicine Co., Ltd. | Not recruiting | 15 Years | 75 Years | All | 180 | Phase 3 | ||
| 13 | NCT03295058 | January 1, 2019 | 10 December 2018 | Peripheral Blood Allogenic Stem Cell Transplantation Using Non-anti Thymocyte Globulin Regimens in Severe Aplastic Anemia Patients | Outcome of Peripheral Blood Allogenic Stem Cell Transplantation Using Non-anti Thymocyte Globulin (ATG ) Conditioning Regimens in Severe Aplastic Anemia Patients | Severe Aplastic Anemia | Drug: Non ATG Conditioning regimen;Drug: GVHD Prophylaxis;Procedure: Allogenic Stem Cell Transplantation;Drug: ATG conditioning regimen | Assiut University | Not recruiting | 16 Years | 50 Years | All | 50 | Phase 2/Phase 3 | ||
| 14 | NCT03821987 | December 17, 2018 | 11 February 2019 | Risk Stratification Directed Conditioning Regimen for Haploidentical HSCT in SAA | Risk Stratification Directed Conditioning Regimen for Haploidentical HSCT in SAA | Aplastic Anemia;Stem Cell Transplant Complications;Engraft Failure | Drug: Fludarabine | Peking University People's Hospital | Recruiting | 3 Years | 55 Years | All | 55 | N/A | China | |
| 15 | NCT03906318 | November 26, 2018 | 15 April 2019 | Expanded Access Use of Itacitinib to Treat a Single Patient With Aplastic Anemia | Drug: Itacitinib | Incyte Corporation | Not recruiting | N/A | N/A | All | N/A | |||||
| No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
| 16 | EUCTR2015-003166-91-NL | 14/11/2018 | 30 April 2019 | A phase II dose escalation study: use of eltrombopag in pediatric patients with severe aplastic anemia or recurrent aplastic anemia | A phase II, open-label, non-controlled, intra-patient dose escalation study to characterize the pharmacokinetics after oral administration of eltrombopag in pediatric patients with refractory, relapsed or treatment naïve severe aplastic anemia or recurrent aplastic anemia. | Refractory, relapsed or treatment naïve severe aplastic anemia (SAA) or recurrent aplastic anemia (AA) MedDRA version: 20.0 Level: PT Classification code 10002967 Term: Aplastic anaemia System Organ Class: 10005329 - Blood and lymphatic system disorders ;Therapeutic area: Diseases [C] - Blood and lymphatic diseases [C15] | Trade Name: REVOLADE Product Name: Eltrombopag Product Code: ETB115 Pharmaceutical Form: Film-coated tablet INN or Proposed INN: ELTROMBOPAG CAS Number: 496775-61-2 Current Sponsor code: ETB115 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 12.5- Trade Name: REVOLADE Product Name: Eltrombopag Product Code: ETB115 Pharmaceutical Form: Film-coated tablet INN or Proposed INN: ELTROMBOPAG CAS Number: 496775-61-2 Current Sponsor code: ETB115 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 25- Product Name: Eltrombopag Product Code: ETB115 Pharmaceutical Form: Film-coated tablet INN or Proposed INN: ELTROMBOPAG CAS Number: 496775-61-2 Current Sponsor code: ETB115 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 100- Trade Name: REVOLADE Product Name: Eltrombopag Product Code: ETB115 Pharmaceutical Form: Powder for oral suspension INN or Proposed INN: ELTROMBOPAG CAS Number: 496775-61-2 Current Sponsor code: ETB115 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 25- Trade Name: REVOLADE Product Name: Eltrombopag Product Code: ETB115 Pharmaceutical Form: Film-coated tablet INN or Proposed INN: ELTROMBOPAG | Novartis Pharma AG | Authorised | Female: yes Male: yes | 60 | Phase 2 | Portugal;United States;Hong Kong;Russian Federation;Netherlands;United Kingdom | |||
| 17 | NCT03579875 | November 13, 2018 | 1 April 2019 | T Cell Receptor a/ß TCD HCT in Patients With Fanconi Anemia | T Cell Receptor Alpha/Beta T Cell Depleted (a/ß TCD) Hematopoietic Cell Transplantation in Patients With Fanconi Anemia (FA) | Fanconi Anemia;Severe Aplastic Anemia;Myelodysplastic Syndromes | Drug: Total Body Irradiation (TBI) (Plan 1);Drug: Cyclophosphamide (CY) (Plan 1);Drug: Fludarabine (FLU);Drug: Methylprednisolone (MP);Device: Donor mobilized PBSC infusion;Drug: G-CSF;Drug: Cyclophosphamide (CY) (Plan 2);Drug: Rituximab | Masonic Cancer Center, University of Minnesota | Recruiting | N/A | 65 Years | All | 48 | Phase 2 | United States | |
| 18 | NCT03955601 | July 12, 2018 | 27 May 2019 | A Novel TBI Free Conditioning Protocol for Haploidentical Transplant in Acquired Aplastic Anemia: | A Novel TBI Free Conditioning Protocol for Haploidentical Hematopoeitic Stem Cell Transplant in Acquired Aplastic Anemia | Aplastic Anemia Idiopathic | Drug: Haploidentical HSCT using TBI free regimen, ''ATG'' with ''Post transplant cyclophosphamide'' | Armed Forces Bone Marrow Transplant Center, Rawalpindi, Pakistan | Recruiting | 2 Years | 60 Years | All | 30 | Phase 2 | Pakistan | |
| 19 | NCT03557099 | June 30, 2018 | 25 June 2018 | A Study to Evaluate the Safety and Efficacy of Hetrombopag Olamine in Severe Aplastic Anemia (SAA) Patient | A Multicentre, Open-label, Single-arm, Phase I/II Study to Evaluate the Safety and Efficacy of Hetrombopag Olamine in Patients With Severe Aplastic Anemia | Severe Aplastic Anemia | Drug: Hetrombopag Olamine | Jiangsu HengRui Medicine Co., Ltd. | Not recruiting | 18 Years | N/A | All | 55 | Phase 1/Phase 2 | China | |
| 20 | NCT03531736 | May 9, 2018 | 24 June 2019 | T Cell Depleted Allogeneic Hematopoietic Stem Cell Transplantation Conditioned With a Reduced Intensity Regimen in Patients With Hematologic Malignancies and Aplastic Anemia | Allogeneic Hematopoietic Stem Cell Transplantation of a/ß T-Lymphocyte Depleted Graft Conditioned With a Reduced Intensity Regimen in Patients With Hematologic Malignancies and Aplastic Anemia | Myeloid Diseases | Drug: Antithymocyte globulin (Rabbit);Drug: fludarabine;Radiation: total body irradiation;Drug: cyclophosphamide;Drug: Rituxan;Procedure: Allogeneic Hematopoietic Stem Cell Transplantation | Memorial Sloan Kettering Cancer Center | Recruiting | 18 Years | N/A | All | 15 | Phase 1 | United States | |
| No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
| 21 | NCT03318159 | April 20, 2018 | 11 June 2018 | Posaconazole Prophylaxis During ATG Treatment for hMDS/AA Patients | Open Label, Phase II Study Investigating the Efficacy of Posaconazole as Prophylaxis Antifungal Agent in Aplastic Anemia / Hypoplastic Myelodysplastic Syndrome Patients Undergoing Antithymocyte Globulin Treatment | Aplastic Anemia;Myelodysplastic Syndromes;Fungal Infection | Drug: Posaconazole | Seoul National University Hospital | Merck Sharp & Dohme Corp. | Recruiting | 18 Years | 75 Years | All | 40 | Phase 2 | Korea, Republic of |
| 22 | NCT03218657 | January 1, 2018 | 16 December 2017 | Clinical Study of Non Severe Aplastic Anemia Treated With Cyclosporine, Androgen and Levamisole | A Prospective, Randomized, Controlled Clinical Study of Non Transfusion Dependent Non Severe Aplastic Anemia Treated With Cyclosporine, Androgen and Levamisole Hydrochloride | Aplastic Anemia | Drug: levamisole hydrochloride;Drug: Androgens;Drug: Cyclosporins | Shengyun Lin | Recruiting | 18 Years | 70 Years | All | 248 | N/A | China | |
| 23 | JPRN-UMIN000030453 | 2017/12/20 | 22 July 2019 | Efficacy of cyclosporine therapy in the treatment of non-severe aplastic anemia | Efficacy of cyclosporine therapy in the treatment of non-severe aplastic anemia - Aplastic anemia 01 study in West Japan Hematology Study Group (W-JHS AA01 study) | aplastic anemia | 1. Start CsA (Neoral or generic drugs emulsified in the same way as Neoral) at a dose of 3.5 mg/kg, bid (before breakfast and before dinner). 2. Measure the blood concentration of cyclosporine at 2 hours (C2) after taking the drug and determine the minimum dose of cyclosporine that produces C2 >600 ng/mL. Continue the dose of cyclosporine for 8 weeks. 3. Continue the treatment for further 44 weeks (a total of 52 weeks) when patients meet the response criteria of HI-E or HI-P at the end of the 8 week treatment. Treatments after the 52 weeks are not specified. When patients do not meet the IWG response criteria 2006 at the end of 8 weeks, the treatment is terminated and treatments after 9 weeks are not specified. | Cooperative study between the West Japan Hematology Study Group and Clinical Research Support Center Kyushu | Recruiting | 16years-old | Not applicable | Male and Female | 33 | Not selected | Japan | |
| 24 | NCT03333486 | December 7, 2017 | 25 June 2018 | Fludarabine Phosphate, Cyclophosphamide, Total Body Irradiation, and Donor Stem Cell Transplant in Treating Patients With Blood Cancer | A Phase II Trial of Haploidentical Allogeneic Stem Cell Transplantation Utilizing Mobilized Peripheral Blood Stem Cells | Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive;Acute Leukemia in Remission;Acute Lymphoblastic Leukemia;Acute Myeloid Leukemia;Acute Myeloid Leukemia With FLT3/ITD Mutation;Acute Myeloid Leukemia With Gene Mutations;Aplastic Anemia;B-Cell Non-Hodgkin Lymphoma;CD40 Ligand Deficiency;Chronic Granulomatous Disease;Chronic Leukemia in Remission;Chronic Lymphocytic Leukemia;Chronic Myelogenous Leukemia, BCR-ABL1 Positive;Chronic Myelomonocytic Leukemia;Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive;Congenital Amegakaryocytic Thrombocytopenia;Congenital Neutropenia;Congenital Pure Red Cell Aplasia;Glanzmann Thrombasthenia;Immunodeficiency Syndrome;Myelodysplastic Syndrome;Myelofibrosis;Myeloproliferative Neoplasm;Paroxysmal Nocturnal Hemoglobinuria;Plasma Cell Myeloma;Polycythemia Vera;Recurrent Non-Hodgkin Lymphoma;Refractory Non-Hodgkin Lymphoma;Secondary Acute Myeloid Leukemia;Secondary Myelodysplastic Syndrome;Severe Aplastic Anemia;Shwachman-Diamond Syndrome;Sickle Cell Disease;T-Cell Non-Hodgkin Lymphoma;Thalassemia;Waldenstrom Macroglobulinemia;Wiskott-Aldrich Syndrome | Drug: Cyclophosphamide;Drug: Fludarabine Phosphate;Other: Laboratory Biomarker Analysis;Procedure: Peripheral Blood Stem Cell Transplantation;Radiation: Total-Body Irradiation | Roswell Park Cancer Institute | National Cancer Institute (NCI) | Recruiting | 1 Year | 75 Years | All | 58 | Phase 2 | United States |
| 25 | NCT03243656 | December 2017 | 16 December 2017 | Eltrombopag in Children With Idiopathic Aplastic Anemia | Randomized Clinical Trial of the Use of Eltrombopag in Children With Idiopathic Aplastic Anemia | Eltrombopag | Drug: Eltrombopag | Assiut University | Not recruiting | 1 Year | 18 Years | All | 20 | Phase 4 | ||
| No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
| 26 | NCT03176849 | November 1, 2017 | 18 December 2018 | A Randomized Phase IV Control Trial of Single High Dose Oral Vitamin D3 in Pediatric Patients Undergoing HSCT | A Randomized Phase IV Control Trial of Single High Dose Oral Vitamin D3 (Stoss Therapy) in Pediatric Patients Undergoing HSCT to Prevent Vitamin D Deficiency and Insufficiency During Transplant | Vitamin D Deficiency;Stem Cell Transplant Complications;Pediatric Cancer;Blood Disorder;Pediatric Acute Myeloid Leukemia;Pediatric Acute Lymphoid Leukemia;Myelodysplastic Syndromes;Sickle Cell Anemia in Children;Aplastic Anemia;Thalassemia in Children | Dietary Supplement: Vitamin D3;Dietary Supplement: Standard Vitamin D3 Supplementation | Phoenix Children's Hospital | Recruiting | 1 Year | 25 Years | All | 50 | Phase 4 | United States | |
| 27 | ChiCTR-ONC-17012896 | 2017-10-01 | 9 October 2017 | Haploidentical Stem Cell Transplantation with Post-Transplant Cyclophosphamide Combined with Short-Term Methotrexate for Severe Aplastic Anemia | Haploidentical Stem Cell Transplantation with Post-Transplant Cyclophosphamide Combined with Short-Term Methotrexate for Severe Aplastic Anemia:a multicenter, prospective, open-label, single-arm II/III phase study | Aplastic Anemia | Case series:Post-Transplant Cyclophosphamide Combined with Short-Term Methotrexate; | Xiangya Hosptial of Central South University | Recruiting | 2 | 65 | Both | Case series:30; | New Treatment Measure Clinical Study | China | |
| 28 | NCT03192397 | August 3, 2017 | 29 April 2019 | Chemotherapy, Total Body Irradiation, and Post-Transplant Cyclophosphamide in Reducing Rates of Graft Versus Host Disease in Patients With Hematologic Malignancies Undergoing Donor Stem Cell Transplant | A Phase II Trial of Fludarabine/Melphalan/Total Body Irradiation With Post Transplant Cyclophosphamide as Graft Versus Host Disease Prophylaxis in Matched-Related and Matched-Unrelated Allogeneic Hematopoietic Cell Transplantation | Acute Myeloid Leukemia in Remission;Adult Acute Lymphoblastic Leukemia in Complete Remission;Chronic Myelogenous Leukemia, BCR-ABL1 Positive in Remission;Chronic Myelomonocytic Leukemia in Remission;Graft Versus Host Disease;Hodgkin Lymphoma;Minimal Residual Disease;Myelodysplastic Syndrome;Myeloproliferative Neoplasm;Non-Hodgkin Lymphoma;Plasma Cell Myeloma;Severe Aplastic Anemia;Waldenstrom Macroglobulinemia | Procedure: Allogeneic Hematopoietic Stem Cell Transplantation;Drug: Cyclophosphamide;Drug: Fludarabine Phosphate;Other: Laboratory Biomarker Analysis;Drug: Melphalan Hydrochloride;Drug: Mycophenolate Mofetil;Drug: Sirolimus;Radiation: Total-Body Irradiation | Roswell Park Cancer Institute | National Cancer Institute (NCI) | Recruiting | 18 Years | 79 Years | All | 30 | Phase 2 | United States |
| 29 | NCT02918292 | July 3, 2017 | 18 December 2018 | Optimizing Haploidentical Aplastic Anemia Transplantation (BMT CTN 1502) | Optimizing Haploidentical Aplastic Anemia Transplantation (CHAMP) (BMT CTN #1502) | Severe Aplastic Anemia | Drug: Cyclophosphamide;Radiation: Total Body Irradiation (TBI);Procedure: Haplo HSCT;Drug: Tacrolimus;Drug: Mycophenolate mofetil (MMF);Drug: G-CSF;Drug: Fludarabine;Drug: Antithymocyte Globulin (ATG) | Medical College of Wisconsin | National Heart, Lung, and Blood Institute (NHLBI);National Cancer Institute (NCI);Blood and Marrow Transplant Clinical Trials Network;National Marrow Donor Program | Recruiting | N/A | 75 Years | All | 30 | Phase 2 | United States |
| 30 | ChiCTR-IOR-17011653 | 2017-07-01 | 19 June 2017 | A prospective, randomized, controlled clinical study of non transfusion dependent non severe aplastic anemia treated with cyclosporine, androgen and levamisole hydrochloride | A prospective, randomized, controlled clinical study of non transfusion dependent non severe aplastic anemia treated with cyclosporine, androgen and levamisole hydrochloride | Aplastic anemia | SA group:none;LSA group:levamisole hydrochloride; | The First affiliated Hospital of Zhejiang Chinese Medical University | Not Recruiting | 18 | 70 | Both | SA group:124;LSA group:124; | Other | China | |
| No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
| 31 | NCT03173937 | June 13, 2017 | 14 October 2019 | Unrelated Umbilical Cord Blood Transplantation for Severe Aplastic Anemia and Hypo-plastic MDS Using CordIn(TM), Umbilical Cord Blood-Derived Ex Vivo Expanded Stem and Progenitor Cells to Expedite Engraftment and Improve Transplant Outcome | Unrelated Umbilical Cord Blood Transplantation for Severe Aplastic Anemia and Hypo-plastic MDS Using CordIn(TM), Umbilical Cord Blood-Derived Ex Vivo Expanded Stem and Progenitor Cells to Expedite Engraftment and Improve Transplant Outcome | Severe Aplastic Anemia;Hypo-Plastic MDS;Myelodysplastic Syndrome (MDS) | Biological: CordIn | National Heart, Lung, and Blood Institute (NHLBI) | Recruiting | 4 Years | 75 Years | All | 68 | Phase 1/Phase 2 | United States | |
| 32 | NCT02998645 | May 11, 2017 | 25 February 2019 | Eltrombopag Combined With Cyclosporine as First Line Therapy in Patients With Severe Acquired Aplastic Anemia | SOAR Trial, A Two-part Study: Interventional Phase II Single-arm Trial to Assess Efficacy and Safety of Eltrombopag Combined With Cyclosporine as First Line Therapy in Patients With Severe Acquired Aplastic Anemia, and an Extension With up to 60-months Follow-up | Severe Aplastic Anemia | Drug: eltrombopag;Drug: Cyclosporine | Novartis Pharmaceuticals | Recruiting | 6 Years | N/A | All | 50 | Phase 2 | Brazil;Hong Kong;Hungary;India;Italy;Korea, Republic of;Netherlands;Spain;Thailand;Turkey | |
| 33 | NCT03025698 | May 11, 2017 | 4 November 2019 | A Phase II Dose-escalation Study Characterizing the PK of Eltrombopag in Pediatric Patients With Previously Untreated or Relapsed Severe Aplastic Anemia or Recurrent Aplastic Anemia | A Phase II, Open-label, Non-controlled, Intra-patient Dose-escalation Study to Characterize the Pharmacokinetics After Oral Administration of Eltrombopag in Pediatric Patients With Refractory, Relapsed or Treatment Naive Severe Aplastic Anemia or Recurrent Aplastic Anemia | Aplastic Anemia | Drug: Eltrombopag;Drug: hATG;Drug: CsA | Novartis Pharmaceuticals | Recruiting | 1 Year | 18 Years | All | 60 | Phase 2 | United States;Hong Kong;Netherlands;Portugal;Russian Federation;Thailand;United Kingdom | |
| 34 | EUCTR2016-002814-29-ES | 21/03/2017 | 28 February 2019 | SOAR Trial: Eltrombopag combined with cyclosporine as first line therapy in patients with severe acquired aplastic anemia with follow-up up to 60-months. | SOAR Trial, A two-part study: Interventional phase II single-arm trial to assess efficacy and safety of Eltrombopag combined with cyclosporine as first line therapy in patients with severe acquired aplastic anemia, and an extension with up to 60-months follow-up. - SOAR | First-line severe aplastic anaemia MedDRA version: 19.0 Level: PT Classification code 10002967 Term: Aplastic anaemia System Organ Class: 10005329 - Blood and lymphatic system disorders ;Therapeutic area: Diseases [C] - Blood and lymphatic diseases [C15] | Trade Name: REVOLADE Product Name: Eltrombopag Product Code: ETB115 Pharmaceutical Form: Film-coated tablet INN or Proposed INN: ELTROMBOPAG CAS Number: 496775-61-2 Current Sponsor code: ETB115 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 25- Trade Name: REVOLADE Product Name: Eltrombopag Product Code: ETB115 Pharmaceutical Form: Film-coated tablet INN or Proposed INN: ELTROMBOPAG CAS Number: 496775-61-2 Current Sponsor code: ETB115 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 50- | Novartis Farmacéutica, S.A | Not Recruiting | Female: yes Male: yes | 50 | Phase 2 | Qatar;Hong Kong;Spain;Turkey;Italy;India;France;Hungary;Mexico;Canada;Brazil;Netherlands;Korea, Republic of | |||
| 35 | EUCTR2016-003226-16-IT | 03/02/2017 | 5 February 2018 | Follow-up of phase I/II study of CaspaCide T cells from an HLA-partially matched family donor after negative selection of TCR aß+ T cells in pediatric patients affected by hematological disorders | Follow-up of phase I/II study of CaspaCide T cells from an HLA-partially matched family donor after negative selection of TCR aß+ T cells in pediatric patients affected by hematological disorders - CaspaCide TCR aß haplo HSCT | Hematological disorders (ALL;AML;Non-Hodgkin lymphoma;Myelodysplastic syndromes;Congenital immune deficiencies;Severe aplastic anemia;Fanconi anemia; Osteopetrosis;Selected cases of hemoglobinopathies) MedDRA version: 19.0 Level: HLGT Classification code 10018849 Term: Haematological disorders NEC System Organ Class: 10005329 - Blood and lymphatic system disorders ;Therapeutic area: Diseases [C] - Blood and lymphatic diseases [C15] | Product Name: AP1903 Pharmaceutical Form: Solution for infusion CAS Number: 195514-63-7 Current Sponsor code: AP1903 Other descriptive name: AP1903 Concentration unit: mg/kg milligram(s)/kilogram Concentration type: equal Concentration number: 0.4- | Bellicum Pharmaceuticals, Inc. | Authorised | Female: yes Male: yes | 175 | Phase 1;Phase 2 | Italy | |||
| No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
| 36 | NCT02838992 | February 2017 | 16 December 2017 | ATG Combined With Cyclophosphamide And Cord Blood Transfusion in Treating Patients With Severe Aplastic Anemia | Multi-center Clinical Study of Immunosuppressants, Cyclophosphamide, And Cord Blood Transfusion in Treating Patients With Severe Aplastic Anemia | Aplastic Anemia | Drug: Rabbit ATG, (Genzyme);Drug: Cy;Drug: CsA;Biological: Cord blood | Jinan Military General Hospital | Shandong University of Traditional Chinese Medicine;Jining Medical University;Affiliated Hospital of Weifang Medical University;Guangzhou First People's Hospital;Harbin Hematology and Oncology Institute;JINING No.1 People's Hospital;JIANGXI Provincal People's Hospital;Jinhua Central Hospital;Linyi People's Hospital;Shandong Cord Blood Bank;Qingdao Center Medical Group;Qingdao University;Taian City Central Hospital;Yantai Yuhuangding Hospital;Yishui Central Hospital of LINYI;Institute of Hematology & Blood Diseases Hospital;Shengjing Hospital | Not recruiting | 1 Year | 60 Years | All | 130 | Phase 4 | China |
| 37 | NCT02960646 | January 18, 2017 | 22 July 2019 | Engineered Donor Stem Cell Transplant in Treating Patients With Hematologic Malignancies | Phase I Clinical Trial Using an Engineered Peripheral Blood Graft for Haploidentical Transplantation | Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome;Acute Myeloid Leukemia in Remission;Adult Acute Lymphoblastic Leukemia in Complete Remission;Aplastic Anemia;Blasts Under 10 Percent of Bone Marrow Nucleated Cells;Chronic Myelogenous Leukemia, BCR-ABL1 Positive;Chronic Myelomonocytic Leukemia;Hematopoietic Cell Transplantation Recipient;Minimal Residual Disease;Myeloproliferative Neoplasm;Plasma Cell Myeloma;Recurrent Chronic Lymphocytic Leukemia;Recurrent Hodgkin Lymphoma;Recurrent Non-Hodgkin Lymphoma;Recurrent Plasma Cell Myeloma;Recurrent Small Lymphocytic Lymphoma;Therapy-Related Myelodysplastic Syndrome | Drug: Cyclophosphamide;Biological: Filgrastim;Drug: Fludarabine Phosphate;Other: Laboratory Biomarker Analysis;Drug: Melphalan;Procedure: Peripheral Blood Stem Cell Transplantation;Biological: Rituximab;Drug: Tacrolimus;Radiation: Total-Body Irradiation | M.D. Anderson Cancer Center | National Cancer Institute (NCI) | Recruiting | 18 Years | 65 Years | All | 12 | Phase 1 | United States |
| 38 | ChiCTR1900023509 | 2017-01-01 | 3 June 2019 | Allogeneic Hematopoietic Stem Cell Transplantation with Risk-adapted Conditioning Regimens for Children with Aplastic Anemia or Refractory Cytopenia of Childhood: a Single-Center Prospective Trial | Allogeneic Hematopoietic Stem Cell Transplantation with Risk-adapted Conditioning Regimens for Children with Aplastic Anemia or Refractory Cytopenia of Childhood: a Single-Center Prospective Trial | aplastic anemia,Refractory Cytopenia of Childhood | 1:Fludarabine150 mg/m2 +Cyclophosphamide200 mg/kg+ Thymoglobuline10mg/kg;2:Fludarabine200 mg/m2 +Cyclophosphamide120 mg/kg+ Thymoglobuline10mg/kg+300cGy TBI;3:Fludarabine200 mg/m2 +Cyclophosphamide120 mg/kg+ Thymoglobuline10mg/kg+ Busulfan 8mg/kg; | Shanghai Children's Medical Center affiliated to Shanghai Jiao Tong University School of Medicine | Recruiting | 18 | Both | 1:50;2:50;3:50; | Phase 0 | China | ||
| 39 | NCT03055078 | January 2017 | 16 December 2017 | Umbilical Cord Derived Mesenchymal Stem Cells Therapy in Aplastic Anemia | Evaluation of Safety and Efficacy in Patients With Aplastic Anemia by Transplantation of Umbilical Cord Derived Mesenchymal Stem Cells | Aplastic Anemia | Biological: mesenchymal stem cells | Hebei Medical University | Recruiting | 14 Years | 60 Years | All | 10 | Phase 1 | China | |
| 40 | NCT02979873 | December 19, 2016 | 11 November 2019 | Sirolimus (Rapamune ) for Relapse Prevention in People With Severe Aplastic Anemia Responsive to Immunosuppressive Therapy | A Randomized Trial of Sirolimus (Rapamune(R)) for Relapse Prevention in Patients With Severe Aplastic Anemia Responsive to Immunosuppressive Therapy | Severe Aplastic Anemia | Drug: Sirolimus | National Heart, Lung, and Blood Institute (NHLBI) | Recruiting | 2 Years | 99 Years | All | 118 | Phase 2 | United States | |
| No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
| 41 | NCT03413306 | December 10, 2016 | 14 October 2019 | Eltrombopag+hATG+CsA vs. hATG+CsA in Children With Severe AA | A Phase II Multicenter Randomized Study of Eltrombopag Combined With Cyclosporine and hATG Versus hATG and CsA as First Line Treatment in Pediatric Patients With Severe Acquired Aplastic Anemia | Acquired Aplastic Anemia | Drug: Eltrombopag;Drug: IST (ATG + CsA) | Federal Research Institute of Pediatric Hematology, Oncology and Immunology | Recruiting | 2 Years | 18 Years | All | 100 | Phase 3 | Russian Federation | |
| 42 | NCT02875743 | December 7, 2016 | 4 February 2019 | King's Invasive Aspergillosis Study II | Incidence of Invasive Fungal Disease in Patients Receiving Immunosuppressive Therapy, Intensive Chemotherapy or Reduced Intensity Haematopoietic Stem Cell Transplantation on Posaconazole Prophylaxis | Aplastic Anemia;Leukemia, Myeloid, Acute;Myelodysplastic Syndromes;Bone Marrow Transplantation | Drug: Posaconazole | King's College Hospital NHS Trust | Not recruiting | 18 Years | N/A | All | 120 | Phase 4 | United Kingdom | |
| 43 | EUCTR2016-001223-31-GB | 11/10/2016 | 3 April 2017 | Incidence of Invasive Fungal Disease in Patients receiving Immunosuppressive Therapy, Intensive Chemotherapy or Reduced Intensity Haematopoietic Stem Cell Transplantation on Posaconazole tablet Prophylaxis | Incidence of Invasive Fungal Disease in Patients receiving Immunosuppressive Therapy, Intensive Chemotherapy or Reduced Intensity Haematopoietic Stem Cell Transplantation on Posaconazole Prophylaxis - King's Invasive Aspergillosis Study II (KIASII) | Aplastic Anaemia, Myelodysplastic syndromes, Acute Myeloid Leukaemia undergoing immunosuppression therapy, high dose chemotherapy or reduced intensity stem cell transplantation MedDRA version: 19.0 Level: LLT Classification code 10038271 Term: Refractory anaemia with excess blasts in transformation System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) MedDRA version: 19.0 Level: LLT Classification code 10059041 Term: Allogeneic peripheral haematopoietic stem cell transplant System Organ Class: 10042613 - Surgical and medical procedures MedDRA version: 19.0 Level: LLT Classification code 10067862 Term: Allogeneic stem cell transplantation System Organ Class: 10042613 - Surgical and medical procedures MedDRA version: 19.0 Level: PT Classification code 10038270 Term: Refractory anaemia with an excess of blasts System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) MedDRA version: 19.0 Level: LLT Classification code 10010776 Term: Constitutional aplastic anaemia System Organ Class: 10005329 - Blood and lymphatic system disorders MedDRA version: 19.0 Level: LLT Classification code 10068063 Term: Aplastic anaemia relapse System Organ Class: 10005329 - Blood and lymphatic system disorders MedDRA version: 19.0 Level: LLT Classification code 10036699 Term: Primary idiopathic aplastic anaemia System Organ Class: 10005329 - Blood and lymphatic system disorders MedDRA version: 19.0 Level: PT Classification code 10000880 Term: Acute myeloid leukaemia System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) MedDRA version: 19.0 Level: PT Classification code 10001756 Term: Allogenic bone marrow transplantation therapy System Organ Class: 10042613 - Surgical and medical procedures MedDRA version: 19.0 Level: LLT Classification code 10000884 Term: Acute myeloid leukaemia NOS System Organ Class: 10029104 - ;Therapeutic area: Diseases [C] - Blood and lymphatic diseases [C15] | Trade Name: Noxafil® Product Name: Noxafil Gastro resistant tablets Pharmaceutical Form: Tablet | King's College Hospital NHS Foundation Trust | Authorised | Female: yes Male: yes | Phase 4 | United Kingdom | ||||
| 44 | NCT02828592 | September 9, 2016 | 20 May 2019 | Haploidentical Bone Marrow Transplant With Post-Transplant Cyclophosphamide for Patients With Severe Aplastic Anemia | A Study of T-Cell Replete, HLA-Mismatched Haploidentical Bone Marrow Transplantation With Post-Transplant Cyclophosphamide for Patients With Severe Aplastic Anemia Lacking HLA-Matched Related Donor | Severe Aplastic Anemia | Drug: Fludarabine;Drug: Cyclophosphamide;Radiation: Total Body Irradiation;Drug: Rabbit ATG | Northside Hospital, Inc. | Recruiting | 1 Year | 75 Years | All | 20 | Phase 2 | United States | |
| 45 | NCT02833805 | September 2016 | 29 July 2019 | NMA Haplo or MUD BMT for Newly Diagnosed Severe Aplastic Anemia | A Phase II Trial of Non-Myeloablative (NMA) Conditioning and Transplantation of Partially HLA-Mismatched/Haploidentical Related or Matched Unrelated Donor (MUD) Bone Marrow for Newly Diagnosed Patients With Severe Aplastic Anemia | Severe Aplastic Anemia;Aplastic Anemia;Bone Marrow Failure;Immunosuppression | Drug: Mycophenolate mofetil;Drug: Tacrolimus;Radiation: Total body irradiation;Drug: Cyclophosphamide;Drug: Fludarabine;Drug: Thymoglobulin | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Recruiting | N/A | N/A | All | 20 | Phase 2 | United States | |
| No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
| 46 | ChiCTR-IOR-16008738 | 2016-08-01 | 18 April 2017 | A single center, randomized, controlled, opened label study for evaluating Cyclosporin alone or combined with Stanozolol in the treatment of aplastic anemia | A single center, randomized, controlled, opened label study for evaluating Cyclosporin alone or combined with Stanozolol in the treatment of aplastic anemia | aplastic anemia | A:Cyclosporin;B:Cyclosporin and Stanozolol; | The First Affiliated Hospital of Zhengzhou University | Recruiting | 18 | 65 | Both | A:100;B:100; | Other | China | |
| 47 | NCT02845596 | August 2016 | 20 May 2019 | Unrelated Donor Transplant Versus Immune Therapy in Pediatric Severe Aplastic Anemia | Unrelated Donor Transplant Versus Immune Therapy in Pediatric Severe Aplastic Anemia | Severe Aplastic Anemia | Drug: cyclosporine;Procedure: Matched Unrelated Donor Hematopoietic Stem Cell Transplant;Drug: horse anti-thymocyte globulin (ATG);Drug: rabbit anti-thymocyte globulin (ATG);Drug: methotrexate;Drug: fludarabine;Drug: cyclophosphamide;Radiation: low-dose total body irradiation (TBI);Procedure: Immunosuppressive Therapy (IST) | Michael Pulsipher, MD | Recruiting | N/A | 25 Years | All | 40 | N/A | United States | |
| 48 | NCT02857530 | August 2016 | 15 August 2016 | Efficacy and Safety of Thrombopoietin In Patients With Severe and Very Severe Aplastic Anemia | Efficacy and Safety of Thrombopoietin In Patients With Severe and Very Severe Aplastic Anemia | Anemia, Aplastic | Drug: rhTPO;Drug: placebo | Tianjin Medical University General Hospital | Not recruiting | 6 Years | 60 Years | Both | 250 | Phase 2 | China | |
| 49 | NCT02773290 | May 2016 | 25 February 2019 | Study of Romiplostim(AMG531) in Subjects With Aplastic Anemia | Phase 2/3 Study of Romiplostim(AMG531) in Subjects With Aplastic Anemia Refractory to or Ineligible for Immunosuppressive Therapy | Aplastic Anemia | Biological: Romiplostim | Kyowa Hakko Kirin Co., Ltd | Not recruiting | 20 Years | N/A | All | 46 | Phase 2/Phase 3 | Japan;Korea, Republic of | |
| 50 | JPRN-JapicCTI-163243 | 01/2/2016 | 16 July 2019 | Phase 2/3 Study of AMG531 in Subjects with Aplastic Anemia | Phase 2/3 Study of AMG531 in Subjects with Aplastic Anemia Refractory to or Ineligible for Immunosuppressive Therapy | Aplastic Anemia | Intervention name : AMG531 INN of the intervention : Romiplostim Dosage And administration of the intervention : Subcutaneous administration | Kyowa Hakko Kirin Co., Ltd. | Not Recruiting | 20 | BOTH | 46 | Phase 2-3 | |||
| No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
| 51 | NCT02745717 | January 2016 | 24 September 2018 | The Efficacy of Immunosuppressive Therapy Combined With Cord Blood Transfusion in Treatment of Severe Aplastic Anemia | The Efficacy of Immunosuppressive Therapy Combined With Cord Blood Transfusion in Treatment of Severe Aplastic Anemia | Severe Aplastic Anemia | Drug: Thymoglobulin;Procedure: Cord blood;Drug: Cyclosporine Oral Product | Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine | Ruijin Hospital;Xinhua Hospital, Shanghai Jiao Tong University School of Medicine;Shanghai Tongji Hospital, Tongji University School of Medicine;Zhejiang Provincial Hospital of TCM | Recruiting | N/A | 60 Years | All | 120 | Phase 4 | China |
| 52 | NCT02566304 | November 13, 2015 | 23 April 2019 | Reduced Intensity Chemotherapy and Radiation Therapy Before Donor Stem Cell Transplant in Treating Patients With Hematologic Malignancies | A Two Step Approach to Non-Myeloablative Allogeneic Hematopoietic Stem Cell Transplantation for Patients With Hematologic Malignancies | Acute Myeloid Leukemia;Acute Myeloid Leukemia in Remission;Aplastic Anemia;Chronic Myelomonocytic Leukemia;Hodgkin Lymphoma;Indolent Non-Hodgkin Lymphoma;Malignant Neoplasm;Myelodysplastic Syndrome;Myeloproliferative Neoplasm;Plasma Cell Myeloma;Refractory Anemia;Refractory Anemia With Excess Blasts;Refractory Anemia With Ring Sideroblasts;Refractory Cytopenia With Multilineage Dysplasia;Refractory Cytopenia With Multilineage Dysplasia and Ring Sideroblasts | Drug: Fludarabine;Radiation: Total-Body Irradiation;Biological: T Cell-Depleted Donor Lymphocyte Infusion;Drug: Cyclophosphamide;Procedure: Peripheral Blood Stem Cell Transplantation;Procedure: Allogeneic Hematopoietic Stem Cell Transplantation;Drug: Tacrolimus;Drug: Mycophenolate mofetil | Sidney Kimmel Cancer Center at Thomas Jefferson University | Recruiting | 18 Years | N/A | All | 30 | Phase 2 | United States | |
| 53 | NCT01861093 | October 16, 2015 | 11 November 2019 | Safety Study of Cord Blood Units for Stem Cell Transplants | A Multicenter Safety Study of Unlicensed, Investigational Cryopreserved Cord Blood Units (CBUs) Manufactured by the National Cord Blood Program (NCBP) and Provided for Unrelated Hematopoietic Stem Cell Transplantation of Pediatric and Adult Patients | Aplastic Anemia;Leukemia;Myelodysplastic Syndrome (MDS);Lymphoma | Biological: Cord Blood Units | National Heart, Lung, and Blood Institute (NHLBI) | National Cancer Institute (NCI);National Institute of Allergy and Infectious Diseases (NIAID);National Cord Blood Program, New York Blood Center | Recruiting | N/A | N/A | All | 500 | Phase 2 | United States |
| 54 | NCT02462252 | October 2015 | 16 December 2017 | Phase IIA Open Label Study to Evaluate Efficacy and Safety of BL-8040 Followed by (hATG), Cyclosporine and Methyprednisolone in Adult Subjects With Aplastic Anemia or Hypoplastic Myelodysplastic Syndrome | A Phase IIA, Open-label Study Designed to Evaluate Efficacy and Safety of BL-8040 Followed by Anti-Thymocyte Globulin (hATG), Cyclosporine and Methylprednisolone in Adult Subjects With Aplastic Anemia (AA) or Hypoplastic Myelodysplastic Syndrome (MDS) | Aplastic Anemia;Hypoplastic Myelodysplastic Syndrome | Drug: BL-8040;Drug: horse anti-thymocyte globulin (hATG);Drug: Methylprednisolone;Drug: Cyclosporine | BioLineRx, Ltd. | Recruiting | 18 Years | N/A | All | 25 | Phase 2 | United States | |
| 55 | NCT02099747 | July 2015 | 26 August 2019 | hATG+CsA vs hATG+CsA+Eltrombopag for SAA | A Prospective Randomized Multicenter Study Comparing Horse Antithymocyte Globuline (hATG) + Cyclosporine A (CsA) With or Without Eltrombopag as Front-line Therapy for Severe Aplastic Anemia Patients. | Severe Aplastic Anemia | Drug: hATG;Drug: CsA;Drug: Eltrombopag | European Group for Blood and Marrow Transplantation | Novartis;Pfizer | Not recruiting | 15 Years | N/A | All | 202 | Phase 3 | France;Italy;Netherlands;Spain;Switzerland;United Kingdom;Germany |
| No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
| 56 | NCT03016806 | June 2015 | 6 May 2019 | Umbilical Cord Blood Transplantation From Unrelated Donors | Umbilical Cord Blood Transplantation From Unrelated Donors | Acute Leukemia;Immune Deficiency Disorder;Congenital Hematological Disorder;Metabolism Disorder;Aplastic Anemia;Myelodysplastic Syndromes;Chronic Leukemia;Lymphoma;Multiple Myeloma;Solid Tumor | Drug: Melphalan;Drug: Fludarabine;Drug: Busulfan;Procedure: Cord Blood Infusion;Drug: Mesna;Drug: Cyclophosphamide;Radiation: Total Body Irradiation 200 cGy;Radiation: Total Body Irradiation 1200 cGy | University of Rochester | Recruiting | 2 Months | 75 Years | All | 30 | Phase 1 | United States | |
| 57 | NCT02404025 | May 2015 | 11 June 2018 | Eltrombopag in Combination With Rabbit Anti-thymocyte Globulin/Cyclosporine A in Naive Aplastic Anemia (AA) Subjects | A Non-randomized, Phase II Study of Eltrombopag in Combination With Rabbit Anti-thymocyte Globulin/Cyclosporine A (ATG/CsA) in Subjects With Moderate or More Severe Aplastic Anemia Who Have Not Received Prior ATG/Anti-lymphocyte Globulin (ALG)-Based Immunosuppressive Therapy | Cytopaenia | Biological: Eltrombopag;Biological: Rabbit ATG;Biological: CsA | Novartis Pharmaceuticals | Not recruiting | 18 Years | 75 Years | All | 11 | Phase 2 | Japan | |
| 58 | EUCTR2014-000174-19-DE | 27/01/2015 | 2 February 2015 | Efficacy and Safety of Eltrombopag in Patients with Acquired Moderate Aplastic Anemia (EMAA) who are treated with Ciclosporin A Prospective Randomized Multicenter Study comparing Thrombopoetin-Receptor agonist Eltrombopag (Revolade®, GlaxoSmithKline) with Placebo in Patients with Acquired Moderate Aplastic Anemia who are treated with Ciclosporin A | Efficacy and Safety of Eltrombopag in Patients with Acquired Moderate Aplastic Anemia (EMAA) who are treated with Ciclosporin A Prospective Randomized Multicenter Study comparing Thrombopoetin-Receptor agonist Eltrombopag (Revolade®, GlaxoSmithKline) with Placebo in Patients with Acquired Moderate Aplastic Anemia who are treated with Ciclosporin A - EMAA | Moderate Aplastic Anemia;Therapeutic area: Diseases [C] - Blood and lymphatic diseases [C15] | Trade Name: Revolade 75 mg Product Name: Eltrombopag Product Code: SB497115 Pharmaceutical Form: Film-coated tablet INN or Proposed INN: Eltrombopag CAS Number: 496775-62-3 Current Sponsor code: SB497115 Other descriptive name: ELTROMBOPAG OLAMINE Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 75- Pharmaceutical form of the placebo: Film-coated tablet Route of administration of the placebo: Oral use | Universitätsklinikum Ulm | Authorised | Female: yes Male: yes | 116 | France;Netherlands;Germany;Italy;United Kingdom;Switzerland | ||||
| 59 | NCT02773225 | January 27, 2015 | 12 February 2018 | Efficacy and Safety of Eltrombopag + CSA in Patients With Moderate Aplastic Anemia (EMAA) | Efficacy and Safety of Thrombopoetin-Receptor Agonist Eltrombopag in in Combination With Ciclosporin A in Moderate Aplastic Anemia (EMAA): Prospective Randomized Multicenter Study | Anemia, Aplastic | Drug: Eltrombopag;Drug: Placebo (for Eltrombopag) | B. Höchsmann | Recruiting | 18 Years | N/A | All | 116 | Phase 2/Phase 3 | Germany | |
| 60 | ChiCTR-IPR-14005720 | 2015-01-01 | 18 April 2017 | A single center, Randomized controlled, opened clinical reserch for evaluating the effectiveness of recombinant human thrombopoietin combined with immunosuppressive therapy in the treatment of newly diagnosed acquired severe aplastic anemia | A single center, Randomized controlled, opened clinical reserch for evaluating the effectiveness of recombinant human thrombopoietin combined with immunosuppressive therapy in the treatment of newly diagnosed acquired severe aplastic anemia | severe aplastic anemia | TPO:rTPO;Ciclosporine:Ciclosporine; | Blood Diseases Hospital, Chinese Academy of Medical Sciences | Recruiting | 18 | 75 | Both | TPO:86;Ciclosporine:86; | Phase 1 study | China | |
| No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
| 61 | NCT02162420 | January 2015 | 7 October 2019 | Hematopoietic Stem Cell Transplant for Dyskeratosis Congenita or Severe Aplastic Anemia | Hematopoietic Stem Cell Transplant for Dyskeratosis Congenita or Severe Aplastic Anemia | Dyskeratosis Congenita;Aplastic Anemia | Drug: Alemtuzumab;Drug: Fludarabine;Drug: Cyclophosphamide;Radiation: Total Body Irradiation;Biological: Stem Cell Transplant;Drug: Anti-thymocyte globulin | Masonic Cancer Center, University of Minnesota | Recruiting | N/A | 70 Years | All | 50 | N/A | United States | |
| 62 | NCT02407470 | January 2015 | 13 April 2015 | Safety and Efficacy of Patient's Own AD-MSC and AD-HSC Transplantation in Patients With Severe Aplastic Anemia | A Multicenter, Randomized, Controlled Study of the Efficacy and Safety of the Combination of Adipose Tissue-derived Hematopoietic Stem Cells (AD-HSCs) and ATG in the Treatment of Severe Aplastic Anemia | Severe Aplastic Anemia | Drug: Rabbit antithymoglobulin (ATG);Procedure: Adipose derived mesenchymal stem cells ( AD-MSCs);Procedure: AD-MSC transdifferentiated HSCs (AD-HSCs) | Navy General Hospital, Beijing | Peking Union Medical College Hospital;General Hospital of Beijing PLA Military Region;Chinese Academy of Medical Sciences | Recruiting | 14 Years | 70 Years | Both | 90 | Phase 1/Phase 2 | China |
| 63 | NCT02203396 | August 2014 | 17 May 2016 | A Single-Arm Phase 2 Study With Optimized Standard Protocol for Severe Aplastic Anemia | A Single-Arm Phase 2 Study With Optimized Standard Protocol for Severe Aplastic Anemia | Aplastic Anemia | Drug: rabbit ATG, Cyclosporine, Levamisole | Yizhou Zheng | Recruiting | 6 Years | 70 Years | Both | 40 | Phase 2 | China | |
| 64 | NCT02224872 | August 2014 | 16 December 2017 | Transplantation of Partially Mismatched Related or Matched Unrelated Bone Marrow for Patients With Refractory Severe Aplastic Anemia | A Phase II Trial of Non-Myeloablative Conditioning and Transplantation of Partially HLA-Mismatched/Haploidentical Related or Matched Unrelated Bone Marrow for Patients With Refractory Severe Aplastic Anemia and Other Bone Marrow Failure Syndromes | Severe Aplastic Anemia;Bone Marrow Failure Syndromes | Procedure: Bone marrow transplant;Drug: Thymoglobulin;Drug: Fludarabine;Drug: Cyclophosphamide;Radiation: TBI;Drug: Mesna;Drug: Tacrolimus;Drug: Mycophenolic acid mofetil | Sidney Kimmel Comprehensive Cancer Center | Recruiting | N/A | 73 Years | All | 20 | Phase 2 | United States | |
| 65 | NCT02148133 | July 23, 2014 | 11 June 2018 | A Study to Assess the Safety and Efficacy of Eltrombopag in Japanese Subjects With Refractory, Moderate or More Severe Aplastic Anemia | A Non-randomized, Open-label, Phase II Study to Assess the Safety and Efficacy of Eltrombopag in Japanese Subjects With Refractory, Moderate or More Severe Aplastic Anemia | Cytopaenia | Drug: Eltrombopag 12.5 mg;Drug: Eltrombopag 25 mg | Novartis Pharmaceuticals | Not recruiting | 18 Years | 79 Years | All | 21 | Phase 2 | Japan | |
| No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
| 66 | NCT01818726 | June 23, 2014 | 16 December 2017 | Safety and Efficacy of Exjade in the Treatment of Transfusion-dependent Iron Overload in Aplastic Anemia Patients | Open-label Study of Exjade in the Treatment of Transfusion-dependent Iron Overload in Aplastic Anemia Patients Undergoing Treatment Programs in Comparison With Control Group | Aplastic Anemia | Drug: ICL670A and standard immunosupressive therapy (Cyclosporine A);Drug: Immunosupressive therapy (Cyclosporine A) | Novartis Pharmaceuticals | Not recruiting | 18 Years | N/A | All | 14 | Phase 4 | Russian Federation | |
| 67 | NCT02094417 | April 14, 2014 | 24 September 2018 | A Phase 2 Study to Evaluate the Efficacy and Safety of AMG531 in Aplastic Anemia | A Phase 2, Randomized, Open-Label, Parallel, Comparative, Dose-Finding Study to Evaluate the Efficacy and Safety of AMG531 in Aplastic Anemia Subjects With Thrombocytopenia Refractory to Immunosuppressive Therapy | Aplastic Anemia | Drug: AMG531 | Kyowa Hakko Kirin Korea Co., Ltd. | Not recruiting | 19 Years | N/A | All | 35 | Phase 2 | Korea, Republic of | |
| 68 | NCT02055456 | February 2014 | 14 December 2015 | Nandrolone Decanoate in the Treatment of Telomeropathies | Male Hormones for Telomere Related Diseases | Aplastic Anemia;Bone Marrow Failure Syndromes;Idiopathic Pulmonary Fibrosis;Telomere Shortening | Drug: Nandrolone Decanoate | University of Sao Paulo | Conselho Nacional de Desenvolvimento Científico e Tecnológico | Recruiting | 2 Years | N/A | Both | 20 | Phase 1/Phase 2 | Brazil |
| 69 | NCT01917708 | January 2014 | 19 November 2018 | BMT Abatacept for Non-Malignant Diseases | Abatacept for Post-Transplant Immune Suppression in Children and Adolescents Receiving Allogeneic Hematopoietic Stem Cell Transplants for Non-Malignant Diseases | Hurler Syndrome;Fanconi Anemia;Glanzmann Thrombasthenia;Wiskott-Aldrich Syndrome;Chronic Granulomatous Disease;Severe Congenital Neutropenia;Leukocyte Adhesion Deficiency;Shwachman-Diamond Syndrome;Diamond-Blackfan Anemia;Dyskeratosis-congenita;Chediak-Higashi Syndrome;Severe Aplastic Anemia;Thalassemia Major;Hemophagocytic Lymphohistiocytosis;Sickle Cell Disease | Drug: Abatacept | Emory University | Not recruiting | N/A | 21 Years | All | 10 | Phase 1 | United States | |
| 70 | NCT02007811 | November 2013 | 19 February 2015 | Open-label Clinical Trial to Investigate the Safety and Tolerability of Allogeneic B-cell Concentrates for Immune Reconstitution After Allogeneic Stem Cell Transplantation Measured as Response to a Antedated Single Vaccination | Prospective, Open-label, Multicentre Clinical Trial, Phase I/IIa, to Investigate the Safety and Tolerability of Allogeneic B-cell Concentrates CD3+-Depleted, CD19+-Enriched, Cryopreserved (Single Administration After Day 120 Following Allogeneic Stem Cell Transplantation (SCT), Donor-identical) in 4 Groups With Escalating Doses for Immune Response Enhancement, Measured as Response to a Antedated Single Vaccination | Acute Myeloid Leukemia;Acute Lymphoblastic Leukemia;Chronic Myeloid Leukemia;Non Hodgkin's Lymphoma;Hodgkin's Disease;Myelodysplastic Syndrome;Multiple Myeloma;Aplastic Anemia | Biological: allogeneic donor derived B-lymphocytes | University of Erlangen-Nürnberg Medical School | University Hospital Regensburg;Wuerzburg University Hospital;University Hospital, Essen;German Research Foundation | Recruiting | 18 Years | 75 Years | Both | 15 | Phase 1/Phase 2 | Germany |
| No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
| 71 | NCT02218437 | October 2013 | 19 February 2015 | Treatment Protocol of Child SAA With the Injection of Mesenchymal Stem Cells(Umbilical Cord Derived) | Child With Severe Aplastic Anemia (SAA) Therapy: the Injection of Umbilical Cord Derived Mesenchymal Stem Cells. | Complications of Organ Transplant Stem Cells Umbilical Cord | Drug: MSC+ATG | Chinese Academy of Medical Sciences | Recruiting | 1 Month | 18 Years | Both | 20 | Phase 4 | China | |
| 72 | NCT02028416 | September 2013 | 11 April 2016 | Comparison of Two Different Doses of Rabbit ATG-Fresenius With Cyclosporin in the Treatment of Acquired Aplastic Anaemia | Protocol for Comparison of Two Different Regimens of Rabbit ATG-Fresenius With Cyclosporin in the Treatment of Acquired Aplastic Anaemia | Aplastic Anemia | Drug: ATG-fresenius | National Institute of Blood Disease Center, Pakistan | Recruiting | 2 Years | 65 Years | Both | 60 | N/A | Pakistan | |
| 73 | NCT02065154 | August 27, 2013 | 15 July 2019 | Post Transplant Cyclophosphamide (Cytoxan) for GvHD Prophylaxis | Phase II Clinical Trial of the Use of Post-Transplant Cyclophosphamide for Graft Versus Host Disease (GvHD) Prophylaxis Following Matched Unrelated Donor (MUD) and Mismatched Unrelated Donor (MMUD)Hematopoietic Stem Cell Transplant (HSCT) | Leukemia;Lymphoma;Myelodysplastic Syndrome;Myelofibrosis;Severe Aplastic Anemia;Allogeneic Transplant | Drug: Cyclophosphamide | University of Alabama at Birmingham | Not recruiting | 19 Years | 65 Years | All | 41 | Phase 2 | United States | |
| 74 | NCT01891994 | June 28, 2013 | 20 August 2018 | Extended Dosing With Eltrombopag for Severe Aplastic Anemia | Extended Dosing With Eltrombopag in Refractory Severe Aplastic Anemia | Severe Aplastic Anemia (SAA) | Drug: Eltrombopag | National Heart, Lung, and Blood Institute (NHLBI) | Not recruiting | 2 Years | 100 Years | All | 40 | Phase 2 | United States | |
| 75 | ChiCTR-PRC-13003130 | 2013-04-01 | 18 April 2017 | Voriconazole tablet for primary prophylaxis of invasive fungal infection in patients with severe aplastic anemia: a prospective, randomized, controlled, multi-center trial | The efficacy and pharmacoeconimics of voriconazole tablet for primary prophylaxis of invasive fungal infection in patients with severe aplastic anemia | Severe Aplastic Anemia (SAA) | Trial group:Vfend? (Voriconazole tablet for oral) should be administered 6mg/kg at the first day for adults, and then 200mg, twice daily; 4-7mg/kg/d for children, divided into twice a day,with administration period no longer than 6 weeks.;control:without anti-fungal drug; | Institute of Hematology & Blood Diseases Hospital, CAMS & PUMC | Not Recruiting | 3 | 65 | Both | Trial group:50;control:50; | Post-market | China | |
| No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
| 76 | NCT01586455 | April 2013 | 8 January 2018 | Human Placental-Derived Stem Cell Transplantation | A Single-Arm Study to Assess the Safety of Transplantation With Human Placental-Derived Stem-Cells Combined With Unrelated and Related Cord Blood in Subjects With Certain Malignant Hematologic Diseases and Non-Malignant Disorders | Mucopolysaccharidosis I;Mucopolysaccharidosis VI;Adrenoleukodystrophy;Niemann-Pick Disease;Metachromatic Leukodystrophy;Wolman Disease;Krabbe's Disease;Gaucher's Disease;Fucosidosis;Batten Disease;Severe Aplastic Anemia;Diamond-Blackfan Anemia;Amegakaryocytic Thrombocytopenia;Myelodysplastic Syndrome;Acute Myelogenous Leukemia;Acute Lymphocytic Leukemia | Drug: Human Placental Derived Stem Cell | New York Medical College | Not recruiting | N/A | 55 Years | All | 43 | Phase 1 | United States | |
| 77 | NCT01966367 | March 2013 | 25 March 2019 | CD34+ (Non-Malignant) Stem Cell Selection for Patients Receiving Allogeneic Stem Cell Transplantation | CD34+ Stem Cell Selection for Patients Receiving a Matched or Partially Matched Family or Unrelated Adult Donor Allogeneic Stem Cell Transplantation for Non-Malignant Disease | Bone Marrow Failure Syndrome;Severe Aplastic Anemia;Severe Congenital Neutropenia;Amegakaryocytic Thrombocytopenia;Diamond-Blackfan Anemia;Schwachman Diamond Syndrome;Primary Immunodeficiency Syndromes;Acquired Immunodeficiency Syndromes;Histiocytic Syndrome;Familial Hemophagocytic Lymphocytosis;Lymphohistiocytosis;Macrophage Activation Syndrome;Langerhans Cell Histiocytosis (LCH);Hemoglobinopathies;Sickle Cell Disease;Sickle Cell-beta-thalassemia | Biological: CD34 Stem Cell Selection Therapy | Diane George, MD | Recruiting | N/A | 40 Years | All | 25 | Early Phase 1 | United States | |
| 78 | NCT02247973 | February 2013 | 19 February 2015 | Mesenchymal Stem Cells Co-transplantation in Alternative Donor Transplantation of Severe Aplastic Anemia. | Phase?Trial of Co-transplantation With Bone Marrow Derived Mesenchymal Stem Cells From Related Donors in Alternative Donor Transplantation of Severe Aplastic Anemia. | Severe Aplastic Anemia | Biological: mesenchymal stem cells | Guangzhou General Hospital of Guangzhou Military Command | Guangzhou First Municipal People’s Hospital;Nanfang Hospital of Southern Medical University;Southern Medical University, China;First Affiliated Hospital, Sun Yat-Sen University;Second Affiliated Hospital, Sun Yat-Sen University;Third Affiliated Hospital, Sun Yat-Sen University;Fifth Affiliated Hospital, Sun Yat-Sen University;Guangdong General Hospital;The Second People's Hospital of GuangDong Province;First Affiliated Hospital of Jinan University;The First Affiliated Hospital of Guangzhou Medical University;Second Affiliated Hospital of Guangzhou Medical University;Peking University Shenzhen Hospital;Shenzhen Second People's Hospital | Recruiting | 14 Years | 50 Years | Both | 100 | Phase 2 | China |
| 79 | NCT01760096 | January 2013 | 19 February 2015 | Safety and Efficacy of Levamisole Combined With Cyclosporine A in Patients With Subclinical Paroxysmal Nocturnal Hemoglobinuria and PNH in the Setting of Another Bone Marrow Failure Syndromes(PNH-2013) | Phase II Study of the Levamisole Combined With Cyclosporine A in Patients With Subclinical Paroxysmal Nocturnal Hemoglobinuria and PNH in the Setting of Another Bone Marrow Failure Syndromes(PNH-2013) | Paroxysmal Nocturnal Hemoglobinuria;Hemoglobinuria;Hemoglobinuria, Paroxysmal;Proteinuria;Urination Disorders;Thrombosis;Bone Marrow Failure;Aplastic Anemia,;Anemia, Hemolytic | Drug: Levamisole+cyclosporin A+Glucocorticoids;Drug: cyclosporin A+Glucocorticoids;Drug: Glucocorticoids | Institute of Hematology & Blood Diseases Hospital | Not recruiting | 18 Years | N/A | Both | 50 | Phase 2 | China | |
| 80 | NCT01849237 | December 2012 | 19 February 2015 | Russian Clinical Trial of Mesenchymal Cells in Patients With Septic Shock and Severe Neutropenia | Russian Single-center Open Randomized Clinical Trial of the Impact of Mesenchymal Stromal Cells Therapy on Organ Dysfunction and 28-day Mortality in Patients With Septic Shock and Severe Neutropenia. | Septic Shock;Nonchemotherapy Drug-induced Neutropenia;Neutropenia After Chemotherapy in Oncohematological Patients;Neutropenia in Patients With Aplastic Anemia | Genetic: Mesenchymal stromal cells;Drug: Standard therapy of septic shock | National Research Center for Hematology, Russia | Recruiting | 17 Years | 75 Years | Both | 30 | Phase 1/Phase 2 | Russian Federation | |
| No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
| 81 | NCT01703169 | November 2012 | 16 December 2017 | Efficacy and Safety of Eltrombopag In Patients With Severe and Very Severe Aplastic Anemia | Efficacy and Safety of Eltrombopag In Patients With Severe and Very Severe Aplastic Anemia | Severe Aplastic Anemia;Very Severe Aplastic Anemia;Moderate Aplastic Anemia | Drug: Eltrombopag | University of Utah | Novartis | Not recruiting | 18 Years | N/A | All | 13 | Phase 2 | United States |
| 82 | NCT01759732 | September 2012 | 19 February 2015 | Haploidentical Stem Cell Transplantation for Children With Acquired Severe Aplastic Anemia | Haploidentical Stem Cell Transplantation With Fixed Dose of T Cells After in Vitro T Cell Depletion Using CD3 Monoclonal Antibody for Children With Acquired Severe Aplastic Anemia | Acquired Aplastic Anemia | Drug: Fludarabine;Drug: Cyclophosphamide;Biological: anti-thymocyte globulin;Biological: filgrastim;Radiation: Total body irradiation;Procedure: CD3-depleted hematopoietic cell transplantation | Asan Medical Center | Recruiting | N/A | 21 Years | Both | 10 | Phase 2 | Korea, Republic of | |
| 83 | NCT01623167 | July 2, 2012 | 22 October 2019 | Eltrombopag With Standard Immunosuppression for Severe Aplastic Anemia | Eltrombopag Added to Standard Immunosuppression in Treatment-Naive Severe Aplastic Anemia | Severe Aplastic Anemia | Drug: hATG/CsA /eltrombopag -Cohort 1;Drug: hATG/CsA /eltrombopag Cohort 2;Drug: hATG/CsA /eltrombopag Cohort 3 | National Heart, Lung, and Blood Institute (NHLBI) | Recruiting | 2 Years | 95 Years | All | 207 | Phase 1/Phase 2 | United States | |
| 84 | NCT01642979 | July 2012 | 19 February 2015 | Safety and Efficacy of Levamisole Combined With Cyclosporine A in Patients With Classic Paroxysmal Nocturnal Hemoglobinuria | Phase II Study of the Levamisole Combined With Cyclosporine A in Patients With Classic Paroxysmal Nocturnal Hemoglobinuria | Paroxysmal Nocturnal Hemoglobinuria;Hemoglobinuria;Hemoglobinuria, Paroxysmal;Proteinuria;Urination Disorders;Thrombosis;Bone Marrow Failure;Aplastic Anemia,;Anemia, Hemolytic | Drug: Levamisole+cyclosporin A+Glucocorticoids;Drug: cyclosporin A+Glucocorticoids;Drug: Glucocorticoids | Institute of Hematology & Blood Diseases Hospital | Not recruiting | 18 Years | N/A | Both | 120 | Phase 2 | China | |
| 85 | NCT01659606 | July 2012 | 15 April 2019 | Radiation- and Alkylator-free Bone Marrow Transplantation Regimen for Patients With Dyskeratosis Congenita | Radiation- and Alkylator-free Hematopoietic Cell Transplantation for Bone Marrow Failure Due to Dyskeratosis Congenita / Telomere Disease | Dyskeratosis Congenita;Hoyeraal Hreidarsson Syndrome;Revesz Syndrome;Aplastic Anemia | Biological: alemtuzumab;Drug: Fludarabine;Drug: Cyclosporins;Drug: Mycophenolate mofetil | Boston Children’s Hospital | Dana-Farber Cancer Institute;Children's Hospital Medical Center, Cincinnati;Children's Hospital Los Angeles;Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium;Baylor College of Medicine;Children's Hospital of Philadelphia;Memorial Sloan Kettering Cancer Center;University of Wisconsin, Madison;Karolinska University Hospital | Recruiting | N/A | 65 Years | All | 40 | Phase 2 | United States;Sweden |
| No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
| 86 | NCT01624805 | June 25, 2012 | 17 June 2019 | Methylprednisolone, Horse Anti-Thymocyte Globulin, Cyclosporine, Filgrastim, and/or Pegfilgrastim or Pegfilgrastim Biosimilar in Treating Patients With Aplastic Anemia or Low or Intermediate-Risk Myelodysplastic Syndrome | Phase II Study of Horse Anti-Thymocyte Globulin (hATG), Cyclosporine, Methylprednisolone, and GCSF (Filgrastim or Pegfilgrastim) in Patients With Aplastic Anemia (AA), or Low/Int-1 Risk Myelodysplastic Syndrome (MDS) | Aplastic Anemia;de Novo Myelodysplastic Syndrome;Myelodysplastic Syndrome;Previously Treated Myelodysplastic Syndrome | Biological: Anti-Thymocyte Globulin;Drug: Cyclosporine;Biological: Filgrastim;Drug: Methylprednisolone;Biological: Pegfilgrastim | M.D. Anderson Cancer Center | National Cancer Institute (NCI) | Recruiting | N/A | N/A | All | 100 | Phase 2 | United States |
| 87 | NCT01844635 | May 2012 | 11 April 2016 | Randomised Study Comparing Different Dosages of Rabbit ATG in Patients With SAA | A Prospective Randomized Multicenter Study Comparing Different Dosages of Rabbit Antithymocyte Globulin (Thymoglobuline) in Patients With Severe Aplastic Anemia | Acquired Aplastic Anemia. | Drug: Thymoglobulin | Nagoya University | Recruiting | N/A | 69 Years | Both | 320 | Phase 3 | Japan | |
| 88 | EUCTR2011-005152-34-ES | 26/03/2012 | 2 October 2017 | Clinical trial to reduce duration of antibiotic therapy in in-hospital patients with haematological diseases that develop fever and low white blood cell count (neutropenia). | Randomized open label clinical trial directed to optimize the duration of empirical antimicrobial therapy in haematologic patients with febrile neutropenia | In-hospital adult patients diagnosed with acute leukemia, lymphoproliferative syndrome, multiple myeloma, myelodysplastic syndrome, aplastic anemia or who have received autologous or allogeneic transplantation of hematopoietic progenitors, with febrile neutropenia without etiological diagnosis. MedDRA version: 14.0 Level: PT Classification code 10016288 Term: Febrile neutropenia System Organ Class: 10005329 - Blood and lymphatic system disorders MedDRA version: 14.0 Level: LLT Classification code 10066156 Term: Empiric treatment System Organ Class: 10042613 - Surgical and medical procedures ;Therapeutic area: Diseases [C] - Bacterial Infections and Mycoses [C01] | Pharmaceutical Form: Powder for solution for infusion INN or Proposed INN: ACICLOVIR CAS Number: 59277-89-3 Current Sponsor code: NA Other descriptive name: ACICLOVIR Concentration unit: mg/kg milligram(s)/kilogram Concentration type: range Concentration number: 5-10 Pharmaceutical Form: Solution for injection INN or Proposed INN: AMIKACIN CAS Number: 37517-28-5 Current Sponsor code: NA Other descriptive name: AMIKACIN Concentration unit: mg/kg milligram(s)/kilogram Concentration type: equal Concentration number: 20- Pharmaceutical Form: Powder for solution for injection or infusion INN or Proposed INN: AMPHOTERICINE B, LIPOSOME CAS Number: 8000078-82-2 Current Sponsor code: NA Other descriptive name: AMPHOTERICINE B, LIPOSOME Concentration unit: mg/kg milligram(s)/kilogram Concentration type: range Concentration number: 3-10 Pharmaceutical Form: Powder for solution for injection or infusion INN or Proposed INN: CASPOFUNGIN ACETATE CAS Number: 179463-17-3 Current Sponsor code: NA Other descriptive name: CASPOFUNGIN ACETATE Concentration unit: mg milligram(s) Concentration type: range Concentration number: 50-70 Pharmaceutical Form: Powder for solution for injection or infusion INN or Proposed INN: CEFEPIME DIHYDROCHLORIDE MONOHYDRATE CAS Number: NA Current Sponsor code: NA Other descriptive name: CEFEPIME DIHYDROCHLORIDE MONOHYDRATE Concentration unit: g gram(s) Concentration type: equal Concentration number: 6- Pharmaceutical Form: Solution for infusion and oral solution INN or Proposed INN: CIPROFLOXACIN CAS Number: 85721-33-1 Current Sponsor code: NA Other descriptive name: CIPROFLOXACIN Concentration unit: mg milligram(s) Concentration type: range Concentration number: 800-1500 Pharmaceutical Form: Tablet INN or Proposed INN: TRIMETHOPRIM SULFATE CAS Number: 56585-33-2 Current Sponsor code: NA Other descriptive name: TRIMETHOPRIM SULFATE Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 160- | José Miguel Cisneros Herreros | Not Recruiting | Female: yes Male: yes | Phase 3 | Spain | ||||
| 89 | NCT01995331 | March 2012 | 19 February 2015 | Moderate-dose Cyclophosphamide for Childhood Acquired Aplastic Anemia | Moderate-dose Cyclophosphamide for Childhood Acquired Aplastic Anemia | Aplastic Anemia | Drug: cyclophosphamide,cyclosporine A | Xiaofan Zhu | Not recruiting | 1 Year | 18 Years | Both | 30 | Phase 4 | China | |
| 90 | NCT01529827 | February 28, 2012 | 30 September 2019 | Fludarabine Phosphate, Melphalan, and Low-Dose Total-Body Irradiation Followed by Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies | A Phase II Trial of Reduced Intensity Allogeneic Stem Cell Transplantation With Fludarabine, Melphalan and Low Dose Total Body Irradiation | Primary Myelofibrosis;Recurrent Adult Acute Lymphoblastic Leukemia;Recurrent Adult Acute Myeloid Leukemia;Recurrent Adult Burkitt Lymphoma;Recurrent Adult Diffuse Large Cell Lymphoma;Recurrent Adult Diffuse Mixed Cell Lymphoma;Recurrent Adult Diffuse Small Cleaved Cell Lymphoma;Recurrent Adult Grade III Lymphomatoid Granulomatosis;Recurrent Adult Hodgkin Lymphoma;Recurrent Adult Immunoblastic Large Cell Lymphoma;Recurrent Adult Lymphoblastic Lymphoma;Recurrent Adult T-cell Leukemia/Lymphoma;Recurrent Childhood Acute Lymphoblastic Leukemia;Recurrent Childhood Acute Myeloid Leukemia;Recurrent Childhood Anaplastic Large Cell Lymphoma;Recurrent Childhood Grade III Lymphomatoid Granulomatosis;Recurrent Childhood Large Cell Lymphoma;Recurrent Childhood Lymphoblastic Lymphoma;Recurrent Childhood Small Noncleaved Cell Lymphoma;Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma;Recurrent Grade 1 Follicular Lymphoma;Recurrent Grade 2 Follicular Lymphoma;Recurrent Grade 3 Follicular Lymphoma;Recurrent Mantle Cell Lymphoma;Recurrent Marginal Zone Lymphoma;Recurrent Mycosis Fungoides/Sezary Syndrome;Recurrent Small Lymphocytic Lymphoma;Recurrent/Refractory Childhood Hodgkin Lymphoma;Refractory Chronic Lymphocytic Leukemia;Refractory Hairy Cell Leukemia;Refractory Multiple Myeloma;Secondary Acute Myeloid Leukemia;Secondary Myelodysplastic Syndromes;Secondary Myelofibrosis;Severe Combined Immunodeficiency;Severe Congenital Neutropenia;Shwachman-Diamond Syndrome;Splenic Marginal Zone Lymphoma;T-cell Large Granular Lymphocyte Leukemia;Waldenstrom Macroglobulinemia;Wiskott-Aldrich Syndrome;Chronic Phase Chronic Myelogenous Leukemia;Congenital Amegakaryocytic Thrombocytopenia;Diamond-Blackfan Anemia;Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue;Hepatosplenic T-cell Lymphoma;Juvenile Myelomonocytic Leukemia;Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable;Nodal Marginal Zone B-cell Lymphoma;Paroxysmal Nocturnal Hemoglobinuria;Peripheral T-cell Lymphoma;Polycythemia Vera;Post-transplant Lymphoproliferative Disorder;Previously Treated Myelodysplastic Syndromes;Accelerated Phase Chronic Myelogenous Leukemia;Adult Acute Lymphoblastic Leukemia in Remission;Adult Acute Myeloid Leukemia in Remission;Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities;Adult Acute Myeloid Leukemia With Del(5q);Adult Acute Myeloid Leukemia With Inv(16)(p13;q22);Adult Acute Myeloid Leukemia With t(15;17)(q22;q12);Adult Acute Myeloid Leukemia With t(16;16)(p13;Adult Acute Myeloid Leukemia With t(8;21)(q22;Adult Grade III Lymphomatoid Granulomatosis;Adult Nasal Type Extranodal NK/T-cell Lymphoma;Anaplastic Large Cell Lymphoma;Angioimmunoblastic T-cell Lymphoma;Aplastic Anemia;Burkitt Lymphoma;Childhood Acute Lymphoblastic Leukemia in Remission;Childhood Acute Myeloid Leukemia in Remission;Childhood Chronic Myelogenous Leukemia;Childhood Diffuse Large Cell Lymphoma;Childhood Grade III Lymphomatoid Granulomatosis;Childhood Immunoblastic Large Cell Lymphoma;Childhood Myelodysplastic Syndromes;Childhood Nasal Type Extranodal NK/T-cell Lymphoma;Chronic Myelomonocytic Leukemia | Drug: fludarabine phosphate;Drug: melphalan;Radiation: total-body irradiation;Drug: tacrolimus;Drug: mycophenolate mofetil;Drug: methotrexate;Other: laboratory biomarker analysis;Procedure: allogeneic hematopoietic stem cell transplantation;Procedure: peripheral blood stem cell transplantation | Roswell Park Cancer Institute | Not recruiting | 3 Years | 75 Years | All | 94 | Phase 2 | United States | |
| No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
| 91 | NCT01553461 | February 21, 2012 | 15 July 2019 | Transplants With Unlicensed Preserved Cord Blood | A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs) for Transplantation in Pediatric and Adult Patients With Hematologic Malignancies and Other Indications | Myelodysplastic Syndrome (MDS);Hematologic Neoplasms;Hematologic Diseases;Severe Aplastic Anemia | Drug: Cord Blood Transplant | National Heart, Lung, and Blood Institute (NHLBI) | Recruiting | N/A | 99 Years | All | 500 | Phase 1/Phase 2 | United States | |
| 92 | NCT01500161 | November 2011 | 19 February 2015 | Pooled Unrelated Donor Umbilical Cord Blood Transplant For Hematologic Malignancy Needing Allogeneic Stem Cell Transplant Without Related HLA-Match | A Phase II Study Of Pooled Unrelated Donor Umbilical Cord Blood (UCB) Transplant For Patients With Hematologic Malignancies Needing Allogeneic Stem Cell Transplant But Do Not Have A Related HLA-Matched Donor | Acute Myelogenous Leukemia;Acute Lymphocytic Leukemia;Chronic Lymphocytic Leukemia;Chronic Myelogenous Leukemia;Hodgkins Disease;Non-Hodgkins Lymphoma;Aplastic Anemia;Multiple Myeloma;Myelodysplastic Syndrome | Drug: Busulfan;Drug: Clofarabine;Drug: Fludarabine;Drug: Melphalan;Drug: Carmustine;Drug: Etoposide;Drug: Cytarabine | Texas Oncology Cancer Center | Not recruiting | 18 Years | 65 Years | Both | 1 | Phase 2 | United States | |
| 93 | NCT01351545 | October 2011 | 8 April 2019 | A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs) | A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs) for Transplantation in Pediatric and Adult Patients With Hematologic Malignancies and Other Indications | Hematologic Malignancies;Inherited Disorders of Metabolism;Inherited Abnormalities of Platelets;Histiocytic Disorders;Acute Myelogenous Leukemia (AML or ANLL);Acute Lymphoblastic Leukemia (ALL);Other Acute Leukemia;Chronic Myelogenous Leukemia (CML);Myelodysplastic (MDS) / Myeloproliferative (MPN) Diseases;Other Leukemia;Hodgkin Lymphoma;Non-hodgkin Lymphoma;Multiple Myeloma/ Plasma Cell Disorder (PCD);Inherited Abnormalities of Erythrocyte Differentiation or Function;Disorders of the Immune System;Automimmune Diseases;Severe Aplastic Anemia | Drug: A multicenter access and distribution protocol for unlicensed cryopreserved cord blood units (CBUs) | Center for International Blood and Marrow Transplant Research | National Marrow Donor Program | Recruiting | N/A | N/A | All | 99999 | N/A | United States |
| 94 | NCT01472055 | October 2011 | 19 February 2015 | Pharmacokinetic Study of Fludarabine in Pediatric Hematopoietic Stem Cell Transplantation | Pharmacokinetic Study of Fludarabine in Pediatric Hematopoietic Stem Cell Transplantation | Acute Leukemia;Chronic Leukemia;Severe Aplastic Anemia | Drug: Fludarabine | Seoul National University Hospital | Ministry of Food and Drug Safety, Korea | Recruiting | N/A | 19 Years | Both | 46 | Phase 2 | Korea, Republic of |
| 95 | NCT01546415 | October 2011 | 19 February 2015 | Safety and Efficacy of Desferasirox in Chinese Patients With Iron Overload and Aplastic Anemia | A Single Arm, Multicenter, Open Label Study of Desferasirox in Chinese Patients With Iron Overload and Aplastic Anemia | Iron Overload | Drug: Desferasirox | Novartis Pharmaceuticals | Not recruiting | 18 Years | N/A | Both | 64 | Phase 4 | China | |
| No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
| 96 | NCT01384513 | August 4, 2011 | 16 December 2017 | A Two-Step Approach to Reduced Intensity Bone Marrow Transplant for Patients With Hematological Malignancies | A Two Step Approach to Reduced Intensity Allogeneic Hematopoietic Stem Cell Transplantation for Patients With Hematologic Malignancies | Adult Acute Lymphoblastic Leukemia in Remission;Adult Acute Myeloid Leukemia in Remission;Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities;Adult Acute Myeloid Leukemia With Del(5q);Adult Acute Myeloid Leukemia With Inv(16)(p13;q22);Adult Acute Myeloid Leukemia With t(15;17)(q22;q12);Adult Acute Myeloid Leukemia With t(16;16)(p13;Adult Acute Myeloid Leukemia With t(8;21)(q22;Adult Nasal Type Extranodal NK/T-cell Lymphoma;Aplastic Anemia;Childhood Acute Lymphoblastic Leukemia in Remission;Childhood Acute Myeloid Leukemia in Remission;Childhood Myelodysplastic Syndromes;Chronic Eosinophilic Leukemia;Chronic Myelomonocytic Leukemia;Chronic Neutrophilic Leukemia;Essential Thrombocythemia;Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue;Juvenile Myelomonocytic Leukemia;Mastocytosis;Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable;Nodal Marginal Zone B-cell Lymphoma;Polycythemia Vera;Previously Treated Myelodysplastic Syndromes;Primary Myelofibrosis;Recurrent Adult Acute Lymphoblastic Leukemia;Recurrent Adult Acute Myeloid Leukemia;Recurrent Adult Diffuse Small Cleaved Cell Lymphoma;Recurrent Adult Grade III Lymphomatoid Granulomatosis;Recurrent Adult Hodgkin Lymphoma;Recurrent Childhood Acute Lymphoblastic Leukemia;Recurrent Childhood Acute Myeloid Leukemia;Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma;Recurrent Grade 1 Follicular Lymphoma;Recurrent Grade 2 Follicular Lymphoma;Recurrent Marginal Zone Lymphoma;Recurrent Mycosis Fungoides/Sezary Syndrome;Recurrent Small Lymphocytic Lymphoma;Recurrent/Refractory Childhood Hodgkin Lymphoma;Refractory Anemia;Refractory Anemia With Ringed Sideroblasts;Refractory Hairy Cell Leukemia;Refractory Multiple Myeloma;Secondary Myelodysplastic Syndromes;Splenic Marginal Zone Lymphoma;T-cell Large Granular Lymphocyte Leukemia;Waldenström Macroglobulinemia | Drug: Fludarabine;Drug: Busulfan;Radiation: Total Body Irradiation (TBI);Biological: Donor Lymphocyte Infusion (DLI);Drug: Cyclophosphamide (CY);Drug: Tacrolimus;Drug: Mycophenolate mofetil;Device: Allogeneic hematopoietic stem cell transplantation;Procedure: Peripheral blood stem cell transplantation (PBSCT) | Sidney Kimmel Cancer Center at Thomas Jefferson University | Recruiting | 18 Years | N/A | All | 50 | Phase 2 | United States | |
| 97 | JPRN-UMIN000006071 | 2011/08/01 | 2 April 2019 | Allogeneic hematopoietic stem cell transplantation for aplastic anemia using low-dose anti-thymocyte globulin | SAA | Conditioning regimen Fludarabine 30mg/m2/day iv day-6,-5,-4,-3 Cyclophosphamide 25mg/kg/day iv day-6,-5,-4,-3 ATG(thymoglobulin) 1.25mg/kg iv day-4,-3 In case of HSCT from unrelated donor or HLA-mismatched related donor, TBI 2Gy day-1 will be added. | Kanto Study Group for Cell Therapy | Not Recruiting | 16years-old | 65years-old | Male and Female | 28 | Phase 2 | Japan | ||
| 98 | NCT01441037 | July 19, 2011 | 20 August 2018 | Danazol for Genetic Bone Marrow and Lung Disorders | Male Hormones for Telomere Related Diseases | Aplastic Anemia | Drug: Danazol | National Heart, Lung, and Blood Institute (NHLBI) | Not recruiting | 2 Years | N/A | All | 27 | Phase 1/Phase 2 | United States | |
| 99 | NCT01408342 | July 2011 | 19 February 2015 | Alemtuzumab and Rituximab in Aplastic Anemia | Low-doses Alemtuzumab and Rituximab Combination as First Line Treatment in Aplastic Anemia | Aplastic Anemia | Drug: Alemtuzumab and Rituximab | Hospital Universitario Dr. Jose E. Gonzalez | Not recruiting | 12 Months | N/A | Both | 0 | N/A | Mexico | |
| 100 | NCT01267643 | May 2011 | 5 February 2018 | Alefacept in Patients With Relapsed/Refractory Aplastic Anemia | A Phase 1/2 Study of Alefacept, a CD2 Receptor Antagonist in Patients With Relapsed/Refractory Aplastic Anemia | Aplastic Anemia | Drug: Alefacept | The Cleveland Clinic | Astellas Pharma US, Inc. | Not recruiting | 18 Years | N/A | All | 4 | Phase 1 | United States |
| No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
| 101 | NCT01328587 | April 1, 2011 | 5 November 2018 | Eltrombopag for Moderate Aplastic Anemia | A Pilot Study of a Thrombopoietin-Receptor Agonist (TPO-R Agonist), Eltrombopag, in Moderate Aplastic Anemia Patients | Moderate Aplastic Anemia;Unilineage Bone Marrow Failure Disorders | Drug: Eltrombopag | National Heart, Lung, and Blood Institute (NHLBI) | Not recruiting | 2 Years | 100 Years | All | 33 | Phase 2 | United States | |
| 102 | NCT01343680 | April 2011 | 19 February 2015 | Trial of Two Central Venous Catheter (CVC) Flushing Schemes in Pediatric Hematology and Oncology Patients | A Randomized Controlled Crossover Trial of Two Different Central Venous Catheter Flushing Schemes in Pediatric Hematology and Oncology Patients in Alberta, Canada | Childhood Cancer;Aplastic Anemia;Metabolic Disorders | Drug: Heparin;Drug: Normal saline | Alberta Children's Hospital | Stollery Children's Hospital | Not recruiting | N/A | 17 Years | Both | 2 | Phase 3 | Canada |
| 103 | NCT01297972 | February 2011 | 19 February 2015 | Mesenchymal Stem Cells in the Treatment of Relapsed/Refractory Severe Acquired Aplastic Anemia | Bone Marrow Mesenchymal Stem Cells in the Treatment of Refractory Severe Acquired Aplastic Anemia | Aplastic Anemia | Biological: Intravenous bone marrow mesenchymal stem cells infusion | University of Sao Paulo | Not recruiting | 18 Years | 65 Years | Both | 9 | Phase 1/Phase 2 | Brazil | |
| 104 | NCT01305694 | February 2011 | 19 February 2015 | Mesenchymal Stem Cells Transplantation to Patients With Relapsed/Refractory Aplastic Anemia. | Phase?/?Trial of Bone Marrow Derived Mesenchymal Stem Cell Transplantation From Related Donor to Patients With Relapsed/Refractory Aplastic Anemia. | Aplastic Anemia | Biological: bone marrow derived mesenchymal stem cells | Guangzhou General Hospital of Guangzhou Military Command | Guangzhou Municipal Twelfth People's Hospital;Guangdong Prevention and Treatment Center for Occupational Diseases | Recruiting | 16 Years | N/A | Both | 50 | Phase 1/Phase 2 | China |
| 105 | NCT01199562 | December 2010 | 6 May 2019 | Infection Prophylaxis and Management in Treating Cytomegalovirus (CMV) Infection in Patients With Hematologic Malignancies Previously Treated With Donor Stem Cell Transplant | Modified Preemptive CMV Management Strategy After Allogeneic Hematopoietic Cell Transplantation and Laboratory Correlation With Innate Immune Function | Hematopoietic/Lymphoid Cancer;Accelerated Phase Chronic Myelogenous Leukemia;Acute Undifferentiated Leukemia;Adult Acute Lymphoblastic Leukemia in Remission;Adult Acute Myeloid Leukemia in Remission;Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities;Adult Acute Myeloid Leukemia With Del(5q);Adult Acute Myeloid Leukemia With Inv(16)(p13;q22);Adult Acute Myeloid Leukemia With t(15;17)(q22;q12);Adult Acute Myeloid Leukemia With t(16;16)(p13;Adult Acute Myeloid Leukemia With t(8;21)(q22;Adult Grade III Lymphomatoid Granulomatosis;Adult Nasal Type Extranodal NK/T-cell Lymphoma;Anaplastic Large Cell Lymphoma;Angioimmunoblastic T-cell Lymphoma;Aplastic Anemia;Atypical Chronic Myeloid Leukemia, BCR-ABL Negative;Blastic Phase Chronic Myelogenous Leukemia;Chronic Eosinophilic Leukemia;Chronic Myelomonocytic Leukemia;Chronic Neutrophilic Leukemia;Chronic Phase Chronic Myelogenous Leukemia;Contiguous Stage II Adult Burkitt Lymphoma;Contiguous Stage II Adult Diffuse Large Cell Lymphoma;Contiguous Stage II Adult Diffuse Mixed Cell Lymphoma;Contiguous Stage II Adult Diffuse Small Cleaved Cell Lymphoma;Contiguous Stage II Adult Immunoblastic Large Cell Lymphoma;Contiguous Stage II Adult Lymphoblastic Lymphoma;Contiguous Stage II Grade 1 Follicular Lymphoma;Contiguous Stage II Grade 2 Follicular Lymphoma;Contiguous Stage II Grade 3 Follicular Lymphoma;Contiguous Stage II Mantle Cell Lymphoma;Contiguous Stage II Marginal Zone Lymphoma;Contiguous Stage II Small Lymphocytic Lymphoma;Cutaneous B-cell Non-Hodgkin Lymphoma;Cytomegalovirus Infection;de Novo Myelodysplastic Syndromes;Essential Thrombocythemia;Extramedullary Plasmacytoma;Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue;Intraocular Lymphoma;Isolated Plasmacytoma of Bone;Mast Cell Leukemia;Meningeal Chronic Myelogenous Leukemia;Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable;Nodal Marginal Zone B-cell Lymphoma;Noncontiguous Stage II Adult Burkitt Lymphoma;Noncontiguous Stage II Adult Diffuse Large Cell Lymphoma;Noncontiguous Stage II Adult Diffuse Mixed Cell Lymphoma;Noncontiguous Stage II Adult Diffuse Small Cleaved Cell Lymphoma;Noncontiguous Stage II Adult Immunoblastic Large Cell Lymphoma;Noncontiguous Stage II Adult Lymphoblastic Lymphoma;Noncontiguous Stage II Grade 1 Follicular Lymphoma;Noncontiguous Stage II Grade 2 Follicular Lymphoma;Noncontiguous Stage II Grade 3 Follicular Lymphoma;Noncontiguous Stage II Mantle Cell Lymphoma;Noncontiguous Stage II Marginal Zone Lymphoma;Noncontiguous Stage II Small Lymphocytic Lymphoma;Polycythemia Vera;Post-transplant Lymphoproliferative Disorder;Previously Treated Myelodysplastic Syndromes;Primary Myelofibrosis;Primary Systemic Amyloidosis;Progressive Hairy Cell Leukemia, Initial Treatment;Prolymphocytic Leukemia;Recurrent Adult Acute Lymphoblastic Leukemia;Recurrent Adult Acute Myeloid Leukemia;Recurrent Adult Burkitt Lymphoma;Recurrent Adult Diffuse Large Cell Lymphoma;Recurrent Adult Diffuse Mixed Cell Lymphoma;Recurrent Adult Diffuse Small Cleaved Cell Lymphoma;Recurrent Adult Grade III Lymphomatoid Granulomatosis;Recurrent Adult Hodgkin Lymphoma;Recurrent Adult Immunoblastic Large Cell Lymphoma;Recurrent Adult Lymphoblastic Lymphoma;Recurrent Adult T-cell Leukemia/Lymphoma;Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma;Recurrent Grade 1 Follicular Lymphoma;Recurrent Grade 2 Follicular Lymphoma;Recurrent Grade 3 Follicular Lymphoma;Recurrent Mantle Cell Lymphoma;Recurrent Marginal Zone Lymphoma;Recurrent Mycosis Fungoides/Sezary Syndrome;Recurrent Small Lymphocytic Lymphoma;Refractory Chronic Lymphocytic Leukemia;Refractory Hairy Cell Leukemia;Refractory Multiple Myeloma;Relapsing Chronic Myelogenous Leukemia;Secondary Acute Myeloid Leukemia;Secondary Myelodysplastic Syndromes;Secondary Myelofibrosis;Splenic Marginal Zone Lymphoma;Stage 0 Chronic Lymphocytic Leukemia;Stage I Adult Burkitt Lymphoma;Stage I Adult Diffuse Large Cell Lymphoma;Stage I Adult Diffuse Mixed Cell Lymphoma;Stage I Adult Diffuse Small Cleaved Cell Lymphoma;Stage I Adult Hodgkin Lymphoma;Stage I Adult Immunoblastic Large Cell Lymphoma;Stage I Adult Lymphoblastic Lymphoma;Stage I Adult T-cell Leukemia/Lymphoma;Stage I Chronic Lymphocytic Leukemia;Stage I Cutaneous T-cell Non-Hodgkin Lymphoma;Stage I Grade 1 Follicular Lymphoma;Stage I Grade 2 Follicular Lymphoma;Stage I Grade 3 Follicular Lymphoma;Stage I Mantle Cell Lymphoma;Stage I Marginal Zone Lymphoma;Stage I Multiple Myeloma;Stage I Mycosis Fungoides/Sezary Syndrome;Stage I Small Lymphocytic Lymphoma;Stage II Adult Hodgkin Lymphoma;Stage II Adult T-cell Leukemia/Lymphoma;Stage II Chronic Lymphocytic Leukemia;Stage II Cutaneous T-cell Non-Hodgkin Lymphoma;Stage II Multiple Myeloma;Stage II Mycosis Fungoides/Sezary Syndrome;Stage III Adult Burkitt Lymphoma;Stage III Adult Diffuse Large Cell Lymphoma;Stage III Adult Diffuse Mixed Cell Lymphoma;Stage III Adult Diffuse Small Cleaved Cell Lymphoma;Stage III Adult Hodgkin Lymphoma;Stage III Adult Immunoblastic Large Cell Lymphoma;Stage III Adult Lymphoblastic Lymphoma;Stage III Adult T-cell Leukemia/Lymphoma;Stage III Chronic Lymphocytic Leukemia;Stage III Cutaneous T-cell Non-Hodgkin Lymphoma;Stage III Grade 1 Follicular Lymphoma;Stage III Grade 2 Follicular Lymphoma;Stage III Grade 3 Follicular Lymphoma;Stage III Mantle Cell Lymphoma;Stage III Marginal Zone Lymphoma;Stage III Multiple Myeloma;Stage III Mycosis Fungoides/Sezary Syndrome;Stage III Small Lymphocytic Lymphoma;Stage IV Adult Burkitt Lymphoma;Stage IV Adult Diffuse Large Cell Lymphoma;Stage IV Adult Diffuse Mixed Cell Lymphoma;Stage IV Adult Diffuse Small Cleaved Cell Lymphoma;Stage IV Adult Hodgkin Lymphoma;Stage IV Adult Immunoblastic Large Cell Lymphoma;Stage IV Adult Lymphoblastic Lymphoma;Stage IV Adult T-cell Leukemia/Lymphoma;Stage IV Chronic Lymphocytic Leukemia;Stage IV Cutaneous T-cell Non-Hodgkin Lymphoma;Stage IV Grade 1 Follicular Lymphoma;Stage IV Grade 2 Follicular Lymphoma;Stage IV Grade 3 Follicular Lymphoma;Stage IV Mantle Cell Lymphoma;Stage IV Marginal Zone Lymphoma;Stage IV Mycosis Fungoides/Sezary Syndrome;Stage IV Small Lymphocytic Lymphoma;T-cell Large Granular Lymphocyte Leukemia;Waldenstrom Macroglobulinemia | Procedure: infection prophylaxis and management;Other: laboratory biomarker analysis;Other: flow cytometry;Genetic: DNA analysis;Genetic: RNA analysis;Procedure: management of therapy complications;Drug: ganciclovir;Drug: valganciclovir;Drug: foscarnet sodium;Procedure: antiviral therapy;Genetic: polymerase chain reaction;Genetic: protein expression analysis | City of Hope Medical Center | National Cancer Institute (NCI) | Not recruiting | 18 Years | N/A | All | 153 | Phase 3 | United States |
| No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
| 106 | JPRN-UMIN000004264 | 2010/11/01 | 2 April 2019 | A Pharmacokinetics (PK)/Phase I study of intravenous (i.v.) administration of mycophenolate mofetil (MMF) for graft-versus-host disease (GVHD) prophylaxis after allogeneic hematopoietic stem cell transplantation (allo-SCT) | Refractory hematologic disorders, including 1. Acute myelogenous leukemia 2. Acute lymphoblastic leukemia 3. Myelodysplastic syndrome 4. Chronic myelogenous leukemia 5. Malignant lymphoma 6. Aplastic anemia | For GVHD prophylaxis, MMF is administered 4-6 h after allo-SCT at a dose of 1000 mg i.v. (diluted to a concentration of 6 mg/ml using 5% Dextrose, over 2 h) thrice daily (or twice daily in the case of cord blood transplantation) from day 0 to day 10 (for up to 14 days). Thereafter, patients are changed to p.o. MMF at the same dose and interval. After day 31, the dose tapers depending on individual risk factors for GVHD. Blood samples (2 ml) for PK analysis are collected in EDTA tubes at 0, 0.5, 1, 2, 4, 8, and 12 h after the morning dose on days 2 and 9 during i.v. MMF administration and at 0, 1, 2, 4, 8, and 12 h on day 16 during p.o. MMF administration. Total mycophenolic acid (MPA) levels are quantified by reverse-phase HPLC. After quantification, non-compartmental analyses of total MPA concentration time data are conducted to estimate the AUC. | Kobe University Graduate School of Medicine | School of Pharmacy and Pharmaceutical Science, Mukogawa Women's University | Not Recruiting | 15years-old | 69years-old | Male and Female | 10 | Not selected | Japan | |
| 107 | NCT01319851 | September 2010 | 16 December 2017 | Alefacept and Allogeneic Hematopoietic Stem Cell Transplantation | Alefacept and Allogeneic Hematopoietic Stem Cell Transplantation for Children With Non-Malignant Diseases Who Have Been Multiply Transfused: a Pilot Study | Thalassemia;Sickle Cell Disease;Glanzmann Thrombasthenia;Wiskott-Aldrich Syndrome;Chronic-granulomatous Disease;Severe Congenital Neutropenia;Leukocyte Adhesion Deficiency;Schwachman-Diamond Syndrome;Diamond-Blackfan Anemia;Fanconi Anemia;Dyskeratosis-congenita;Chediak-Higashi Syndrome;Severe Aplastic Anemia | Drug: Alefacept | Emory University | Children's Healthcare of Atlanta | Not recruiting | N/A | 21 Years | All | 3 | N/A | United States |
| 108 | NCT01182662 | August 2010 | 19 February 2015 | Safety and Efficacy Study of Umbilical Cord/Placenta-Derived Mesenchymal Stem Cells to Treat Severe Aplastic Anemia | Phase II Study of Umbilical Cord/Placenta-Derived Mesenchymal Stem Cells to Treat SAA | Aplastic Anemia | Other: Human umbilical cord-derived MSCs and cyclosporin A;Other: cyclosporin A | Shandong University | National Natural Science Foundation of China | Recruiting | 18 Years | 80 Years | Both | 30 | Phase 2 | China |
| 109 | NCT01187017 | August 2010 | 19 October 2017 | A Pilot Study of Fludarabine Plus Cyclophosphamide in Refractory Severe Aplastic Anemia | A Pilot Study of Fludarabine Plus Cyclophosphamide in Refractory Severe Aplastic Anemia | Aplastic Anemia;Neutropenia;Pancytopenia;Severe Aplastic Anemia | Drug: Cyclophosphamide;Drug: Fludarabine | National Heart, Lung, and Blood Institute (NHLBI) | Not recruiting | 2 Years | N/A | All | 1 | Phase 1/Phase 2 | United States | |
| 110 | NCT01191749 | August 2010 | 16 December 2017 | Alemtuzumab in Myelodysplastic Syndrome (MDS), Aplastic Anemia, and T-Cell Large Granular Lymphocytic Leukemia (T-GL) | Phase II Pilot Study Of Alemtuzumab In Patients With Low Or INT-1 Risk Myelodysplastic Syndrome (MDS), Aplastic Anemia (AA), Or T-Cell Large Granular Lymphocytic Leukemia (T-LGL) | Leukemia | Drug: Alemtuzumab | M.D. Anderson Cancer Center | Not recruiting | N/A | N/A | All | 7 | Phase 2 | United States | |
| No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
| 111 | NCT01193283 | August 2010 | 16 December 2017 | Cyclophosphamide Plus Cyclosporine in Treatment-Naive Severe Aplastic Anemia | Cyclophosphamide Plus Cyclosporine in Treatment-Naive Severe Aplastic Anemia | Aplastic Anemia;Neutropenia;Pancytopenia;Severe Aplastic Anemia | Drug: Cyclophosphamide;Drug: Cyclosporine | National Heart, Lung, and Blood Institute (NHLBI) | Not recruiting | 2 Years | N/A | All | 22 | Phase 1/Phase 2 | United States | |
| 112 | NCT01350245 | July 2010 | 19 October 2017 | Bone Marrow Transplantation of Patients in Remission Using Partially Matched Relative Donor | A Two Step Approach to Allogeneic Hematopoietic Stem Cell Transplantation for Patients With Hematologic Malignancies in Remission From HLA Partially-Matched Related Donors | Acute Myeloid Leukemia;Myelodysplastic Syndromes;Biphenotypic Leukemia;Acute Lymphocytic Leukemia;Chronic Myeloid Leukemia;Chronic Lymphocytic Leukemia;Plasma Cell Neoplasms;Lymphoma;Hodgkin's Disease;Aplastic Anemia | Radiation: Total Body Irradiation (TBI);Biological: Donor Lymphocyte Infusion (DLI);Drug: Cyclophosphamide;Drug: Mycophenolate Mofetil (MMF);Drug: Tacrolimus;Device: Hematopoietic stem cell transplantation (HSCT) | Sidney Kimmel Cancer Center at Thomas Jefferson University | Not recruiting | 18 Years | N/A | All | 28 | Phase 2 | United States | |
| 113 | NCT01145976 | March 2010 | 19 February 2015 | Comparison of Cy-Atg vs Flu-Atg for the Conditioning Therapy in Allo-HCT for Adult Aplastic Anemia | Randomized Comparison of Cyclophosphamide Versus Fludarabine in Addition to Anti-thymocyte Globulin for the Conditioning Therapy in Allogeneic Hematopoietic Cell Transplantation for Adult Acquired Aplastic Anemia | Aplastic Anemia | Drug: Cy-ATG;Drug: Flu-ATG | Cooperative Study Group A for Hematology | Recruiting | 15 Years | 65 Years | Both | 98 | Phase 3 | Korea, Republic of | |
| 114 | NCT01129323 | November 2009 | 19 February 2015 | Reduced-Intensity Preparative Regimen for Allogeneic Stem Cell Transplantation in Patients With Severe Aplastic Anemia | Reduced-Intensity Preparative Regimen for Allogeneic Stem Cell Transplantation in Patients With Severe Aplastic Anemia | Severe Aplastic Anemia | Drug: Cyclophosphamide, Fludarabine, Rabbit ATG | City of Hope Medical Center | Not recruiting | N/A | 21 Years | Both | 0 | N/A | United States | |
| 115 | EUCTR2008-005594-35-BE | 28/10/2009 | 27 January 2014 | Randomized double-blind study of mesenchymal stem cells (MSC) in patients undergoing matched unrelated allogeneic bone marrow or peripheral blood stem cell transplantation- A European multicentre study. - NA | Randomized double-blind study of mesenchymal stem cells (MSC) in patients undergoing matched unrelated allogeneic bone marrow or peripheral blood stem cell transplantation- A European multicentre study. - NA | Hematological disorders of the following types: ALL: acute lymphoblastic leukemia in complete remission (<5% blasts in marrow) up to and including third remission (excluding relapse). AML: acute myelocytic leukemia in remission (excluding relapse). CML: chronic myelocytic leukemia who are in the chronic phase of the disease. Severe aplastic anemia, hemoglobinopathies (thalassemia major). Inborn errors of metabolism. Myelodysplastic syndromes MedDRA version: 9.1 Level: LLT Classification code 10027703 Term: Mismatched donor bone marrow transplantation therapy | Product Name: Mesenchymal stem cells Product Code: MSC Pharmaceutical Form: Intravenous infusion Pharmaceutical form of the placebo: Solution for injection Route of administration of the placebo: Intravenous use | CHU Sart-Tilman | Authorised | Female: yes Male: yes | 172 | Belgium | ||||
| No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
| 116 | NCT00987480 | September 25, 2009 | 16 December 2017 | Hematopoietic Stem Cell Transplantation for the Treatment of Patients With Fanconi Anemia Lacking a Genotypically Identical Donor, Using a Chemotherapy Only Cytoreduction With Busulfan, Cyclophosphamide and Fludarabine | A Multicenter Phase II Trial of Hematopoietic Stem Cell Transplantation for the Treatment of Patients With Fanconi Anemia Lacking a Genotypically Identical Donor, Using a Chemotherapy Only Cytoreduction With Busulfan, Cyclophosphamide and Fludarabine | Aplastic Anemia;Leukemia;Myelodysplastic Syndrome | Drug: Busulfan, fludarabine, & cyclophosphamide with immunosuppression with ATG and cyclosporine.;Device: CliniMACS device | Memorial Sloan Kettering Cancer Center | Boston Children’s Hospital;Children's Hospital Medical Center, Cincinnati;Children's Hospital and Health System Foundation, Wisconsin;Rockefeller University;Fred Hutchinson Cancer Research Center | Not recruiting | N/A | N/A | All | 11 | Phase 2 | United States |
| 117 | NCT00944749 | July 2009 | 16 December 2017 | Horse ATG/CsA in Aplastic Anemia Patients Unresponsive to or With a Suboptimal Response to Rabbit ATG/CsA Treatment | Horse ATG/CsA in Aplastic Anemia Patients Unresponsive to or With a Suboptimal Response to Rabbit ATG/CsA Treatment | Anemia, Aplastic;Anemia, Hypoplastic | Drug: h-ATG (ATGAM );Drug: Cyclosporine (Gengraf ) | National Heart, Lung, and Blood Institute (NHLBI) | Not recruiting | 2 Years | 82 Years | All | 23 | Phase 2 | United States | |
| 118 | NCT01105273 | July 2009 | 19 February 2015 | Human Leukocyte Antigen (HLA)-Haploidentical Hematopoietic Stem Cell Transplantation for Patients With Aplastic Anemia | HLA-haploidentical Allogeneic Hematopoietic Cell Transplantation Using CD3±CD19 Depletion for Patients With Aplastic Anemia After Conditioning of Fludarabine, Cyclophosphamide and Antithymocyte Globulin | Aplastic Anemia | Biological: anti-thymocyte globulin;Biological: filgrastim;Drug: Fludarabine;Drug: Cyclophosphamide;Procedure: CD3±CD19 depleted hematopoietic stem cell transplantation | Asan Medical Center | Not recruiting | N/A | 21 Years | Both | 12 | Phase 1/Phase 2 | Korea, Republic of | |
| 119 | NCT01224496 | July 2009 | 16 December 2017 | Traditional Chinese Medicine in the Supportive Management of Anaemic and Cytopenic (Leukopenia, Thrombocytopenia) Haematological Disorders | Traditional Chinese Medicine in the Supportive Management of Anaemic and Cytopenic (Leukopenia, Thrombocytopenia) Haematological Disorders | Myelodysplastic Syndrome (MDS);Aplastic Anaemia (AA);Myelofibrosis (MF);Thalassemia Intermedia | Drug: Chinese herbal concoction twice a day for 6 months | Singapore General Hospital | Shanghai Yueyang Integrated Medicine Hospital;Singapore Bao Zhong Tang TCM Center | Not recruiting | 13 Years | 85 Years | All | 38 | Phase 1/Phase 2 | Singapore |
| 120 | NCT00922883 | May 29, 2009 | 25 March 2019 | A Pilot Study of the Thrombopoietin-Receptor Agonist Eltrombopag in Refractory Aplastic Anemia Patients | A Pilot Study of a Thrombopoietin-Receptor Agonist (TPO-R Agonist), Eltrombopag, in Aplastic Anemia Patients With Immunosuppressive-Therapy Refractory Thrombocytopenia | Anemia, Aplastic;Anemia, Hypoplastic;Thrombocytopenia | Drug: Eltrombopag | National Heart, Lung, and Blood Institute (NHLBI) | Not recruiting | 12 Years | N/A | All | 43 | Phase 2 | United States | |
| No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
| 121 | EUCTR2009-012746-23-IT | 12/05/2009 | 19 March 2012 | pilot study of second line therapy for AAA Acquired Aplastic Anemia with antithymocyte globulin, cyclosporin and etanercept - ND | pilot study of second line therapy for AAA Acquired Aplastic Anemia with antithymocyte globulin, cyclosporin and etanercept - ND | acquired aplastic anemia MedDRA version: 9.1 Level: SOC Classification code 10005329 | Trade Name: ENBREL*SC 4FL 25MG+4SIR 1ML Pharmaceutical Form: Powder and solvent for solution for injection INN or Proposed INN: Etanercept Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 25- | ISTITUTO GIANNINA GASLINI | Authorised | Female: yes Male: yes | Italy | |||||
| 122 | NCT00856388 | January 14, 2009 | 18 December 2018 | Fludarabine Phosphate, Melphalan, Total-Body Irradiation, Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer or Bone Marrow Failure Disorders | A Pilot Trial Of Reduced Intensity Allogeneic Stem Cell Transplantation With Fludarabine, Melphalan, And Low Dose Total Body Irradiation | Accelerated Phase Chronic Myelogenous Leukemia;Acute Myeloid Leukemia With Multilineage Dysplasia Following Myelodysplastic Syndrome;Adult Acute Lymphoblastic Leukemia in Remission;Adult Acute Myeloid Leukemia in Remission;Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities;Adult Acute Myeloid Leukemia With Del(5q);Adult Acute Myeloid Leukemia With Inv(16)(p13;q22);Adult Acute Myeloid Leukemia With t(15;17)(q22;q12);Adult Acute Myeloid Leukemia With t(16;16)(p13;Adult Acute Myeloid Leukemia With t(8;21)(q22;Adult Nasal Type Extranodal NK/T-cell Lymphoma;Anaplastic Large Cell Lymphoma;Angioimmunoblastic T-cell Lymphoma;Aplastic Anemia;Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative;Childhood Acute Lymphoblastic Leukemia in Remission;Childhood Acute Myeloid Leukemia in Remission;Childhood Chronic Myelogenous Leukemia;Childhood Diffuse Large Cell Lymphoma;Childhood Immunoblastic Large Cell Lymphoma;Childhood Myelodysplastic Syndromes;Childhood Nasal Type Extranodal NK/T-cell Lymphoma;Chronic Eosinophilic Leukemia;Chronic Myelomonocytic Leukemia;Chronic Neutrophilic Leukemia;Chronic Phase Chronic Myelogenous Leukemia;de Novo Myelodysplastic Syndromes;Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue;Fanconi Anemia;Juvenile Myelomonocytic Leukemia;Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable;Nodal Marginal Zone B-cell Lymphoma;Noncontiguous Stage II Adult Burkitt Lymphoma;Noncontiguous Stage II Adult Diffuse Large Cell Lymphoma;Noncontiguous Stage II Adult Diffuse Mixed Cell Lymphoma;Noncontiguous Stage II Adult Diffuse Small Cleaved Cell Lymphoma;Noncontiguous Stage II Adult Immunoblastic Large Cell Lymphoma;Noncontiguous Stage II Adult Lymphoblastic Lymphoma;Noncontiguous Stage II Grade 1 Follicular Lymphoma;Noncontiguous Stage II Grade 2 Follicular Lymphoma;Noncontiguous Stage II Grade 3 Follicular Lymphoma;Noncontiguous Stage II Mantle Cell Lymphoma;Noncontiguous Stage II Marginal Zone Lymphoma;Noncontiguous Stage II Small Lymphocytic Lymphoma;Paroxysmal Nocturnal Hemoglobinuria;Previously Treated Myelodysplastic Syndromes;Primary Myelofibrosis;Recurrent Adult Acute Lymphoblastic Leukemia;Recurrent Adult Acute Myeloid Leukemia;Recurrent Adult Burkitt Lymphoma;Recurrent Adult Diffuse Large Cell Lymphoma;Recurrent Adult Diffuse Mixed Cell Lymphoma;Recurrent Adult Diffuse Small Cleaved Cell Lymphoma;Recurrent Adult Grade III Lymphomatoid Granulomatosis;Recurrent Adult Hodgkin Lymphoma;Recurrent Adult Immunoblastic Large Cell Lymphoma;Recurrent Adult Lymphoblastic Lymphoma;Recurrent Adult T-cell Leukemia/Lymphoma;Recurrent Childhood Acute Lymphoblastic Leukemia;Recurrent Childhood Acute Myeloid Leukemia;Recurrent Childhood Anaplastic Large Cell Lymphoma;Recurrent Childhood Grade III Lymphomatoid Granulomatosis;Recurrent Childhood Large Cell Lymphoma;Recurrent Childhood Lymphoblastic Lymphoma;Recurrent Childhood Small Noncleaved Cell Lymphoma;Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma;Recurrent Grade 1 Follicular Lymphoma;Recurrent Grade 2 Follicular Lymphoma;Recurrent Grade 3 Follicular Lymphoma;Recurrent Mantle Cell Lymphoma;Recurrent Marginal Zone Lymphoma;Recurrent Mycosis Fungoides/Sezary Syndrome;Recurrent Small Lymphocytic Lymphoma;Recurrent/Refractory Childhood Hodgkin Lymphoma;Refractory Chronic Lymphocytic Leukemia;Refractory Multiple Myeloma;Relapsing Chronic Myelogenous Leukemia;Secondary Acute Myeloid Leukemia;Secondary Myelodysplastic Syndromes;Splenic Marginal Zone Lymphoma;Stage III Adult Diffuse Small Cleaved Cell Lymphoma;Stage III Adult Immunoblastic Large Cell Lymphoma;Stage III Adult Lymphoblastic Lymphoma;Stage III Grade 1 Follicular Lymphoma;Stage III Grade 2 Follicular Lymphoma;Stage III Grade 3 Follicular Lymphoma;Stage III Mantle Cell Lymphoma;Stage III Marginal Zone Lymphoma;Stage III Small Lymphocytic Lymphoma;Stage IV Adult Burkitt Lymphoma;Stage IV Adult Diffuse Small Cleaved Cell Lymphoma;Stage IV Adult Immunoblastic Large Cell Lymphoma;Stage IV Adult Lymphoblastic Lymphoma;Stage IV Grade 1 Follicular Lymphoma;Stage IV Grade 2 Follicular Lymphoma;Stage IV Grade 3 Follicular Lymphoma;Stage IV Mantle Cell Lymphoma;Stage IV Marginal Zone Lymphoma;Stage IV Small Lymphocytic Lymphoma;Waldenström Macroglobulinemia | Procedure: allogeneic hematopoietic stem cell transplantation;Biological: anti-thymocyte globulin;Drug: fludarabine phosphate;Drug: melphalan;Radiation: total-body irradiation | Roswell Park Cancer Institute | National Cancer Institute (NCI) | Not recruiting | 3 Years | 75 Years | All | 62 | N/A | United States |
| 123 | NCT00993694 | January 2009 | 16 December 2017 | Methemoglobinemia in Young Patients With Hematologic Cancer or Aplastic Anemia Treated With Dapsone | Dapsone Induced Methemoglobinemia in Pediatric Hematologic Malignancy and Aplastic Anemia | Chronic Myeloproliferative Disorders;Leukemia;Lymphoma;Lymphoproliferative Disorder;Methemoglobinemia;Multiple Myeloma and Plasma Cell Neoplasm;Myelodysplastic Syndromes;Myelodysplastic/Myeloproliferative Neoplasms;Nonmalignant Neoplasm | Drug: chemotherapy;Drug: dapsone;Other: medical chart review;Procedure: assessment of therapy complications | Vanderbilt University | National Cancer Institute (NCI) | Not recruiting | N/A | 18 Years | All | 41 | N/A | United States |
| 124 | NCT00882323 | November 2008 | 19 February 2015 | Reduced Toxicity Fludarabine (Flu) + Cyclophosphamide (CPM) + Rabbit Antithymocyte Globulin (rATG) Conditioning Regimen for Unrelated Donor Transplantation in Severe Aplastic Anemia (SAA) | Reduced Toxicity Fludarabine, Cyclophosphamide Plus Thymoglobulin Conditioning Regimen for Unrelated Donor Transplantation in Severe Aplastic Anemia | Aplastic Anemia | Drug: Cyclophosphamide, Fludarabine, Thymoglobulin | The Korean Society of Pediatric Hematology Oncology | Recruiting | 1 Year | 21 Years | Both | 33 | Phase 2 | Korea, Republic of | |
| 125 | NCT00471848 | August 2008 | 19 February 2015 | Rabbit Antithymocyte Globulin (Thymoglobuline) With Ciclosporin for Patients With Acquired Aplastic Anaemia | Prospective Phase II Study of Rabbit Antithymocyte Globulin (ATG, Thymoglobuline®, Genzyme) With Ciclosporin for Patients With Acquired Aplastic Anaemia and Comparison With Matched Historical Patients Treated With Horse ATG and Ciclosporin | Aplastic Anemia | Drug: rabbit antithymocyte globulin | European Group for Blood and Marrow Transplantation | Genzyme, a Sanofi Company | Not recruiting | 16 Years | N/A | Both | 35 | Phase 2 | France;Germany;Italy;Saudi Arabia;Switzerland;United Kingdom |
| No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
| 126 | NCT00604201 | May 21, 2008 | 11 November 2019 | Stem Cell Transplant Using Peripheral and Cord Blood Stem Cells to Treat Severe Aplastic Anemia and Myelopdysplastic Syndrome | Co-Infusion of Umbilical Cord Blood and Haploidentical CD34+ Cells Following Nonmyeloablative Conditioning as Treatment for Severe Aplastic Anemia and MDS Associated With Severe Neutropenia Refractory to Immunosuppressive Therapy | Myelodysplastic Syndrome (MDS) With Refractory Anemia (RA);Severe Aplastic Anemia (SAA) | Biological: Umbilical Cord Blood | National Heart, Lung, and Blood Institute (NHLBI) | Not recruiting | 4 Years | 75 Years | All | 67 | Phase 2 | United States | |
| 127 | NCT01530555 | April 2008 | 14 March 2016 | Prospective Phase II Study of Rabbit Antithymocyte Globulin (ATG, Thymoglobuline®, Genzyme) With Ciclosporin for Patients With Acquired Aplastic Anaemia | Prospective Phase II Study of Rabbit Antithymocyte Globulin (ATG, Thymoglobuline®, Genzyme) With Ciclosporin for Patients With Acquired Aplastic Anaemia | Acquired Aplastic Anaemia | Drug: Rabbit ATG, Thymoglobuline (Genzyme) | King Faisal Specialist Hospital & Research Center | Not recruiting | 16 Years | 80 Years | Both | 35 | Phase 2 | ||
| 128 | EUCTR2007-001657-26-GB | 29/02/2008 | 26 November 2018 | Single Centre Phase II Pilot study of Unrelated Cord Blood Transplantation in Patients with Poor Risk Haematological Malignancies. | Single Centre Phase II Pilot study of Unrelated Cord Blood Transplantation in Patients with Poor Risk Haematological Malignancies. | 1. Acute, chronic leukaemia or myelodysplastic syndrome for which allogeneic transplantation is considered as the best treatment option. 2. Acute lymphoblastic leukaemia (ALL) 3. Non-Hodgkin’s lymphoma 4. Hodgkin’s disease 5. Chronic lymphocytic leukaemia. 6. Acquired bone marrow failure syndromes 7. Other haematological malignancies for which UD bone marrow transplantation is indicated MedDRA version: 9.1 Level: LLT Classification code 10000880 Term: Acute myeloid leukaemia MedDRA version: 9.1 Level: LLT Classification code 10028533 Term: Myelodysplastic syndrome MedDRA version: 9.1 Level: LLT Classification code 10009013 Term: Chronic myeloid leukaemia MedDRA version: 9.1 Level: LLT Classification code 10000844 Term: Acute lymphoblastic leukaemia MedDRA version: 9.1 Level: LLT Classification code 10020328 Term: Hodgkin's lymphoma MedDRA version: 9.1 Level: LLT Classification code 10029593 Term: Non-Hodgkin's lymphoma NOS MedDRA version: 9.1 Level: LLT Classification code 10003892 Term: B-cell chronic lymphocytic leukaemia/prolymphocytic leukaemia/small lymphocytic lymphoma MedDRA version: 9.1 Level: LLT Classification code 10002968 Term: Aplastic anaemia, unspecified | Trade Name: Fludarabine Pharmaceutical Form: Concentrate for solution for infusion INN or Proposed INN: FLUDARABINE PHOSPHATE CAS Number: 75607-67-9 Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 25- Trade Name: Busilvex Pharmaceutical Form: Concentrate for solution for infusion INN or Proposed INN: BUSULFAN CAS Number: 55-98-1 Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 6- Trade Name: Thymoglobulin Pharmaceutical Form: Powder for solution for infusion CAS Number: 0 Other descriptive name: RABBIT HUMAN T LYMPHOCYTE IMMUNOGLOBULIN Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 25- Trade Name: Thiotepa Pharmaceutical Form: Powder for injection* INN or Proposed INN: THIOTEPA CAS Number: 52244 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 15- Trade Name: Cyclophosphamide Pharmaceutical Form: Powder and solvent for solution for infusion CAS Number: 6055192 Other descriptive name: CYCLOPHOSPHAMIDE MONOHYDRATE Concentration unit: g gram(s) Concentration type: equal Concentration number: 1- Trade Name: Alkeran Pharmaceutical Form: Powder for infusion* INN or Proposed INN: MELPHALAN CAS Number: 148-82-3 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 50- | King's College Hospital NHS Foundation Trust | Not Recruiting | Female: yes Male: yes | 27 | Phase 2 | United Kingdom | |||
| 129 | NCT00556400 | November 2007 | 19 October 2017 | Treatment of Menorrhagia in Women With Thrombocytopenia Using Platelets or Platelets and Hormones | Treatment of Menorrhagia in Women With Thrombocytopenia: Comparison of Platelet Transfusion Alone to Platelet Transfusion With Continuous Oral Contraceptive Pills | Aplastic Anemia;Menorrhagia;Amenorrhea | Drug: Lo-Ovral Oral Contraceptive Pills;Drug: Placebo - sugar pill | Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) | Not recruiting | 12 Years | 55 Years | Female | 1 | Phase 1/Phase 2 | United States | |
| 130 | NCT00455312 | August 2007 | 16 December 2017 | Stem Cell Transplant (SCT) for Dyskeratosis Congenita or SAA | Hematopoietic Stem Cell Transplant For Patients With Dyskeratosis Congenita and Severe Aplastic Anemia | Dyskeratosis Congenita;Aplastic Anemia | Drug: Campath 1H;Drug: Cyclophosphamide;Drug: Fludarabine;Procedure: Total Body Irradiation;Procedure: Stem Cell Transplantation;Drug: antithymocyte globulin;Drug: Methylprednisolone | Masonic Cancer Center, University of Minnesota | Not recruiting | N/A | 70 Years | All | 36 | Phase 2/Phase 3 | United States | |
| No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
| 131 | NCT00673114 | August 2007 | 19 October 2017 | Unrelated Cord Blood Transplant Plus a Haplo-Identical (Half-Matched), T-Cell Depleted Stem Transplant From a Related Donor for Subjects With High Risk Malignancies | A Prospective, Phase I/II Trial Determining the Efficacy and Safety of Allogeneic Hematopoietic Stem Cell Transplantation Using Banked Unrelated Umbilical Cord Blood Supplemented With Related, Haplo-Identical T-Cell Depleted Stem Cells in Subjects With High Risk Malignancies | Hematologic Malignancy;Myelodysplastic Syndrome (MDS);Aplastic Anemia | Biological: haplo/cord transplant | Joanne Kurtzberg, MD | Miltenyi Biotec GmbH | Not recruiting | N/A | 55 Years | All | 3 | Phase 1/Phase 2 | United States |
| 132 | EUCTR2006-006577-25-SE | 25/07/2007 | 19 March 2012 | A prospective randomized study comparing rapamune and tacrolimus vs. cyclosporine and methotrexate as immune prophylaxis in allogeneic hematopoietic stem cell transplantation, using HLA-A, -B, -DRB1 identical related or unrelated donors. A Nordic multicenter study. - Rapa + FK in stem cell transplantation | A prospective randomized study comparing rapamune and tacrolimus vs. cyclosporine and methotrexate as immune prophylaxis in allogeneic hematopoietic stem cell transplantation, using HLA-A, -B, -DRB1 identical related or unrelated donors. A Nordic multicenter study. - Rapa + FK in stem cell transplantation | Graft versus host disease prophylaxis in patients receiving stem cell transplantation due to: chronic myeloid leukemia (CML) in 1st or 2nd chronic phase, acute myeloid leukemia (AML) in complete remission, acute lymphoblastic leukemia (ALL) in complete remission, myelodysplastic syndrome, chronic lymphocytic leukemia, lymphoma, non-malignant disorders, severe aplastic anemia, hemoglobinopathies and metabolic disorders MedDRA version: 9.1 Level: LLT Classification code 10018799 Term: GVHD | Trade Name: Rapamune Product Name: Rapamune Pharmaceutical Form: Tablet INN or Proposed INN: SIROLIMUS CAS Number: 53123889 Other descriptive name: Rapamycin Concentration unit: µg/ml microgram(s)/millilitre Concentration type: range Concentration number: 3-12 Trade Name: Prograf Product Name: Prograf Pharmaceutical Form: Capsule* INN or Proposed INN: TACROLIMUS CAS Number: 104987113 Other descriptive name: FK-506 Concentration unit: µg/ml microgram(s)/millilitre Concentration type: range Concentration number: 5-15 Trade Name: Sandimmun Neoral Product Name: Sandimmun Neoral Pharmaceutical Form: Capsule, soft INN or Proposed INN: CICLOSPORIN CAS Number: 59865133 Other descriptive name: CsA Concentration unit: µg/ml microgram(s)/millilitre Concentration type: range Concentration number: 100-300 Trade Name: Methotrexate Product Name: Methotrexate Pharmaceutical Form: Injection* INN or Proposed INN: METHOTREXATE CAS Number: 59052 Other descriptive name: MTX Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 25- | Karolinska Institutet | Authorised | Female: yes Male: yes | 200 | Finland;Sweden | ||||
| 133 | NCT00578266 | February 2007 | 16 December 2017 | Allogeneic Stem Cell Transplantation for Patients With Severe Aplastic Anemia | Allogeneic Stem Cell Transplantation for Patients With Severe Aplastic Anemia, Using Matched Unrelated Donors and Mismatched Related Donors | Anemia, Aplastic | Drug: Cyclophosphamide,Campath IH and TBI | Mayo Clinic | Not recruiting | N/A | 60 Years | All | 8 | Phase 1 | United States | |
| 134 | NCT00895739 | June 2006 | 19 February 2015 | Alemtuzumab and Low-Dose Cyclosporine in Treating Patients With Severe Aplastic Anemia or Acquired Marrow Failure | Alemtuzumab and Low-Dose Cyclosporine-A as Alternative Immunosuppressive Treatment for Severe Aplastic Anemia (SAA) and Single-Lineage Aplastic Patients | Nonmalignant Neoplasm | Biological: alemtuzumab;Drug: cyclosporine | Federico II University | Recruiting | 18 Years | N/A | Both | 50 | Phase 2 | Italy | |
| 135 | NCT00358657 | May 24, 2006 | 28 October 2019 | Fludarabine Phosphate, Cyclophosphamide, and Total-Body Irradiation Followed by Donor Bone Marrow Transplant and Cyclophosphamide, Mycophenolate Mofetil, Tacrolimus, and Sirolimus in Treating Patients With Primary Immunodeficiency Disorders or Noncancerous Inherited Disorders | HLA-Haploidentical Related Marrow Grafts for the Treatment of Primary Immunodeficiencies and Other Nonmalignant Disorders Using Conditioning With Low-Dose Cyclophosphamide, TBI and Fludarabine and Postgrafting Cyclophosphamide | Immunodeficiency Syndrome;Non-Cancer Diagnosis;Severe Aplastic Anemia;Donor | Procedure: Allogeneic Bone Marrow Transplantation;Drug: Cyclophosphamide;Drug: Fludarabine Phosphate;Other: Laboratory Biomarker Analysis;Drug: Mycophenolate Mofetil;Procedure: Nonmyeloablative Allogeneic Hematopoietic Stem Cell Transplantation;Drug: Sirolimus;Drug: Tacrolimus;Radiation: Total-Body Irradiation | Fred Hutchinson Cancer Research Center | National Cancer Institute (NCI);National Heart, Lung, and Blood Institute (NHLBI) | Not recruiting | N/A | 55 Years | All | 14 | Phase 2 | United States |
| No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
| 136 | NCT00319878 | May 2006 | 19 February 2015 | Sirolimus and Cyclosporine for Treatment-Resistant Aplastic Anemia | A Phase I/II Trial of Sirolimus (Rapamune) and Cyclosporine in Patients With Refractory Aplastic Anemia | Anemia, Aplastic | Drug: Sirolimus;Drug: Cyclosporine | Office of Rare Diseases (ORD) | Rare Diseases Clinical Research Network | Recruiting | 21 Years | N/A | Both | 52 | Phase 1/Phase 2 | United States |
| 137 | NCT00474747 | February 7, 2006 | 16 December 2017 | Fludarabine-Based Conditioning for Allogeneic Marrow Transplantation in Aplastic Anemia | Fludarabine-Based Conditioning for Allogeneic Marrow Transplantation From HLA-Compatible Unrelated Donors in Severe Aplastic Anemia | Aplastic Anemia | Drug: Antithymocyte Globulin;Drug: Cyclophosphamide;Drug: Fludarabine;Radiation: Total Body Irradiation (TBI);Procedure: Bone Marrow Transplant | M.D. Anderson Cancer Center | National Heart, Lung, and Blood Institute (NHLBI);National Cancer Institute (NCI) | Not recruiting | N/A | 65 Years | All | 5 | Phase 1/Phase 2 | United States |
| 138 | NCT00343785 | February 2006 | 16 December 2017 | Cyclophosphamide and Anti-thymocyte Globulin Followed By Methotrexate and Cyclosporine in Preventing Chronic Graft-Versus-Host Disease in Patients With Severe Aplastic Anemia Undergoing Donor Bone Marrow Transplant | Cyclophosphamide and Antithymocyte Globulin Conditioning Regimen for Marrow Transplantation From HLA-Matched Family Members for Severe Aplastic Anemia: Effect of Marrow Cell Dose on Chronic Graft-vs.-Host Disease: A Multi-Center Trial | Aplastic Anemia | Drug: cyclophosphamide;Biological: anti-thymocyte globulin;Drug: cyclosporine;Procedure: allogeneic bone marrow transplantation;Drug: methotrexate;Genetic: DNA analysis;Other: flow cytometry;Genetic: polymorphism analysis;Other: laboratory biomarker analysis | Fred Hutchinson Cancer Research Center | National Heart, Lung, and Blood Institute (NHLBI) | Not recruiting | N/A | 65 Years | All | 21 | Phase 2 | United States;Canada |
| 139 | NCT00354419 | February 2006 | 19 February 2015 | Cyclophosphamide, Antithymocyte Globulin, and Total-Body Irradiation in Treating Patients With Severe Aplastic Anemia Undergoing Umbilical Cord Blood Transplant | A Dose Finding Study of Total Body Irradiation for Conditioning Patients With Severe Aplastic Anemia Transplanted With Umbilical Cord Blood | Aplastic Anemia | Radiation: total-body irradiation;Drug: cyclophosphamide;Biological: anti-thymocyte globulin;Drug: cyclosporine;Procedure: umbilical cord blood transplantation;Drug: mycophenolate mofetil;Procedure: bone marrow aspiration;Genetic: DNA analysis;Biological: filgrastim | Fred Hutchinson Cancer Research Center | National Cancer Institute (NCI) | Not recruiting | N/A | 40 Years | Both | 30 | Phase 1 | United States |
| 140 | NCT00326417 | January 2006 | 16 December 2017 | Fludarabine-based Conditioning for Severe Aplastic Anemia (BMT CTN 0301) | Fludarabine-based Conditioning for Allogeneic Marrow Transplantation From HLA-compatible Unrelated Donors in Severe Aplastic Anemia (BMT CTN #0301) | Anemia, Aplastic | Drug: Fludarabine;Drug: Cyclophosphamide 150mg;Drug: Cyclophosphamide 100mg;Drug: Cyclophosphamide 50mg | Medical College of Wisconsin | National Heart, Lung, and Blood Institute (NHLBI);Blood and Marrow Transplant Clinical Trials Network;National Cancer Institute (NCI);National Marrow Donor Program | Not recruiting | N/A | 65 Years | All | 97 | Phase 1/Phase 2 | United States |
| No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
| 141 | NCT00737685 | January 2006 | 19 February 2015 | Flu+CPM+rATG Conditioning Regimes for Unrelated Bone Marrow Transplantation (UBMT)(or Mobilized Peripheral Blood)in Severe Aplastic Anemia (SAA) | Fludarabine, Cyclophosphamide Plus Thymoglobulin Conditioning Regimen for Unrelated Bone Marrow (or Mobilized Peripheral Blood) Transplantation in Severe Aplastic Anemia | Anemia, Aplastic | Drug: cyclophosphamide, fludarabine , thymoglobulin | The Korean Society of Pediatric Hematology Oncology | Not recruiting | N/A | 25 Years | Both | 30 | Phase 2 | Korea, Republic of | |
| 142 | NCT00260689 | November 28, 2005 | 16 December 2017 | Three Immunosuppressive Treatment Regimens for Severe Aplastic Anemia | A Randomized Study of Three Immunosuppressive Regimens in Treatment Naive Patients With Severe Aplastic Anemia: Horse ATG/CsA Taper vs Rabbit-ATG/CsA vs Alemtuzumab | Immunosuppresion;Thrombocytopenia;Pancytopenia;Neutropenia | Biological: Anti-thymocyte globulin (rabbit);Biological: Anti-thymocyte globulin (horse);Drug: Cyclosporine;Drug: Alemtuzumab | National Heart, Lung, and Blood Institute (NHLBI) | Not recruiting | 2 Years | N/A | All | 136 | Phase 2 | United States | |
| 143 | NCT00438178 | October 2005 | 19 February 2015 | Safety and Efficacy of Obatoclax Mesylate (GX15-070MS) for the Treatment of Hematological Malignancies | A Phase I Study of Obatoclax Mesylate (GX15-070MS) in Patients With Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS), Chronic Myeloid Leukemia (CML)in Myeloid Blast Phase, Myelofibrosis, Previously-Treated Chronic Lymphocytic Leukemia (CLL), or Aplastic Anemia | Hematological Malignancies | Drug: Obatoclax mesylate (GX15-070MS) | Gemin X | Not recruiting | 18 Years | N/A | Both | 44 | Phase 1 | United States;Canada | |
| 144 | NCT00195624 | September 15, 2005 | 5 November 2018 | Alemtuzumab to Treat Severe Aplastic Anemia | A Pilot Study of Alemtuzumab (Campath) in Patients With Relapsed or Refractory Severe Aplastic Anemia | Severe Aplastic Anemia, Refractory;Severe Aplastic Anemia, Relapse | Biological: Alemtuzumab (Campath );Drug: Cyclosporine | National Heart, Lung, and Blood Institute (NHLBI) | Not recruiting | 2 Years | 110 Years | All | 47 | Phase 2 | United States | |
| 145 | NCT00229619 | September 2005 | 19 October 2017 | Rituximab to Treat Moderate Aplastic Anemia, Pure Red Cell Aplasia, or Diamond Blackfan Anemia | A Pilot Study of Recombinant Humanized Anti- Cluster of Differentiation Antigen 20 (Anti-CD20) Antibody (Rituximab) in Patients With Moderate Aplastic Anemia, Pure Red Cell Aplasia, or Diamond Blackfan Anemia | Anemia, Aplastic;Red-Cell Aplasia, Pure;Anemia, Diamond-Blackfan | Drug: Rituximab | National Heart, Lung, and Blood Institute (NHLBI) | Not recruiting | 2 Years | N/A | All | 11 | Phase 2 | United States | |
| No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
| 146 | NCT00676806 | July 2005 | 16 December 2017 | A Phase II Study of Umbilical Cord Blood Transplantation | A Phase II Study of Umbilical Cord Blood Transplantation Following Myeloablative or Reduced-Intensity Conditioning | Leukemia;Lymphoma;Multiple Myeloma;Aplastic Anemia | Biological: Umbilical Cord Blood After Myeloablative Conditioning;Biological: Umbilical Cord Blood After Reduced-Intensity Conditioning | Tufts Medical Center | Not recruiting | N/A | 70 Years | All | 7 | Phase 2 | United States | |
| 147 | NCT00295997 | May 2005 | 19 February 2015 | Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer, Metastatic Kidney Cancer, or Aplastic Anemia | Non-myeloablative Allogeneic Stem Cell Transplantation With Match Unrelated Donors for Treatment of Hematologic Malignancies and Renal Cell Carcinoma and Aplastic Anemia | Chronic Myeloproliferative Disorders;Kidney Cancer;Leukemia;Lymphoma;Multiple Myeloma and Plasma Cell Neoplasm;Myelodysplastic Syndromes;Myelodysplastic/Myeloproliferative Neoplasms | Biological: anti-thymocyte globulin;Biological: filgrastim;Biological: graft-versus-tumor induction therapy;Biological: therapeutic allogeneic lymphocytes;Drug: busulfan;Drug: cyclophosphamide;Drug: fludarabine phosphate;Drug: methotrexate;Drug: mycophenolate mofetil;Drug: tacrolimus;Procedure: allogeneic bone marrow transplantation;Procedure: nonmyeloablative allogeneic hematopoietic stem cell transplantation;Procedure: peripheral blood stem cell transplantation | University of California, San Francisco | National Cancer Institute (NCI) | Not recruiting | N/A | 74 Years | Both | 35 | N/A | United States |
| 148 | NCT00806598 | May 2005 | 19 October 2017 | Thymoglobulin and Cyclosporine in Patients With Aplastic Anemia or Myelodysplastic Syndrome | Phase II Study of Combination of Thymoglobulin, Cyclosporine, Methylprednisone, and Granulocyte Colony-stimulating Factor (GCSF) in Patients With Newly Diagnosed Aplastic Anemia or With Hypoplastic or Low/Intermediate-1 Risk Myelodysplastic Syndrome | Myelodysplastic Syndrome;Aplastic Anemia | Drug: Thymoglobulin;Drug: Cyclosporine;Drug: Methylprednisolone;Drug: G-CSF | M.D. Anderson Cancer Center | Genzyme, a Sanofi Company | Not recruiting | 15 Years | N/A | All | 53 | Phase 2 | United States |
| 149 | NCT01231841 | March 2005 | 19 October 2017 | Anti-thymocyte Globulin and Cyclosporine as First-Line Therapy in Treating Patients With Severe Aplastic Anemia | Protocol for Prospective Phase II Study of Rabbit Antithymocyte Globulin (r-ATG/Thymoglobulin) and Cyclosporine (CsA) as a First Line Immunosuppressive (IS) Therapy for Severe Aplastic Anemia (sAA) | Aplastic Anemia | Drug: cyclosporine;Other: flow cytometry;Biological: anti-thymocyte globulin | The Cleveland Clinic | Not recruiting | 12 Years | N/A | All | 20 | Phase 2 | United States | |
| 150 | EUCTR2004-004914-18-IT | 21/01/2005 | 7 January 2013 | A pilot multicentric study for the use of the anti-TNF alfa in patients with: 1) Fanconi Anemia with marrow failure with no bone marrow compatible donor 2) In patients with acquired aplastic anemia failing immunosuppression and with no bone marrow donor | A pilot multicentric study for the use of the anti-TNF alfa in patients with: 1) Fanconi Anemia with marrow failure with no bone marrow compatible donor 2) In patients with acquired aplastic anemia failing immunosuppression and with no bone marrow donor | Marrow failure in patients refractary/non eligible to conventional treatments;Therapeutic area: Diseases [C] - Blood and lymphatic diseases [C15] | Trade Name: ENBREL*SC 4FL 25MG+4SIR 1ML Pharmaceutical Form: Powder and solvent for solution for injection INN or Proposed INN: Etanercept CAS Number: 185243-69-0 Concentration unit: mg milligram(s) Concentration number: .4- | ISTITUTO GIANNINA GASLINI | Authorised | Female: yes Male: yes | Italy | |||||
| No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
| 151 | JPRN-C000000356 | 2004/12/01 | 2 April 2019 | Evaluation of the safety and efficacy of allogeneic hematopoietic stem cell transplantation (HSCT) using alemtuzumab for patients with aplastic anemia | Aplastic anemia | Alemtuzumab is added to the fludarabine-based regimen at 0.16 – 0.25 mg/kg per day for 6 days (days -10 to -5). | GCP-ISS HE0403 group | Not Recruiting | 20years-old | 65years-old | Male and Female | 38 | Phase 1,2 | Japan | ||
| 152 | NCT00065260 | July 2003 | 19 October 2017 | Rabbit Antithymocyte Globulin Versus Campath-1H for Treating Severe Aplastic Anemia | A Randomized Trial of Immunosuppression in Aplastic Anemia Patients With Refractory Pancytopenia or Suboptimal Hematologic Response After h-ATG/CsA Treatment | Aplastic Anemia | Drug: Campath-1H;Drug: r-ATG;Drug: CsA | National Heart, Lung, and Blood Institute (NHLBI) | Not recruiting | 2 Years | N/A | All | 54 | Phase 2 | United States | |
| 153 | NCT00061360 | May 23, 2003 | 14 October 2019 | Improving Immunosuppressive Treatment for Patients With Severe Aplastic Anemia | A Randomized Trial of a Novel Immunosuppressive Combination of ATG, CsA and Sirolimus (Rapamune) vs a Slow Taper Cyclosporine Regimen in Subjects With Severe Aplastic Anemia | Severe Aplastic Anemia | Drug: ATG+Rapamune+cyclosporine;Drug: ATG+cyclosporine | National Heart, Lung, and Blood Institute (NHLBI) | Not recruiting | 2 Years | 110 Years | All | 77 | Phase 2 | United States | |
| 154 | NCT00186797 | December 2002 | 19 February 2015 | Purified CD34+ Hematopoietic Stem Cell Transplantation From Alternate Donors for Patients With Severe Aplastic Anemia | Aplastic Anemia | Procedure: Allogeneic stem cell transplant;Drug: Fludarabine, Cyclophosphamide | St. Jude Children's Research Hospital | Not recruiting | N/A | 21 Years | Both | 28 | N/A | United States | ||
| 155 | NCT00533923 | December 2002 | 8 August 2016 | Nonmyeloablative Allogeneic Stem Cell Transplantation From HLA-Matched Unrelated Donor for the Treatment of Hematologic Disorders | Nonmyeloablative Allogeneic Stem Cell Transplantation From HLA-Matched Unrelated Donor for the Treatment of Hematologic Disorders | AML;ALL;CLL;Myelodysplastic Syndrome;Non-Hodgkin's Lymphoma;Hodgkin's Lymphoma;Multiple Myeloma;Aplastic Anemia;Myeloproliferative Disorder | Drug: Cyclophosphamide; Fludarabine; Cyclosporin; CAMPATH-1H (Alemtuzumab); GM-CSF | Beth Israel Deaconess Medical Center | Bayer | Not recruiting | N/A | 65 Years | Both | 25 | Phase 2 | United States |
| No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
| 156 | NCT00399971 | November 2002 | 19 February 2015 | Safety and Efficacy Study of Ex Vivo Immunotherapy for Treatment of Aplastic Anemia | Phase I/II Study of An Ex Vivo Immunotherapy for Treatment of Idiopathic Aplastic Anemia | Anemia, Aplastic | Procedure: Ex Vivo Immunotherapy;Drug: Ex vivo immunotherapy | Shenzhen Zhongxing Yangfan Biotech Co. Ltd. | The 12th Guangzhou Municipal Hospital;Liu Hua Qiao Hospital | Recruiting | 10 Years | 80 Years | Both | 100 | Phase 1/Phase 2 | China |
| 157 | NCT00516152 | November 2002 | 19 February 2015 | Phase II Study Evaluating Busulfan and Fludarabine as Preparative Therapy in Adults With Hematopoietic Disorders Undergoing MUD SCT | Phase II Study Evaluating Busulfan and Fludarabine as Preparative Therapy in Adults With Hematopoietic Disorders Undergoing Matched Unrelated Donor Stem Cell Transplantation | Chronic Myeloid Leukemia;Acute Myelogenous Leukemia;Myelodysplasia;Acute Lymphocytic Leukemia;Severe Aplastic Anemia;Non-Hodgkin's Lymphoma;Lymphoproliferative Disease;Multiple Myeloma;Advanced Myeloproliferative Disease | Drug: Busulfan/Fludarabine phosphate/Tacrolimus/Methotrexate/G-CSF | University of California, San Francisco | Not recruiting | 15 Years | 61 Years | Both | 36 | Phase 2 | United States | |
| 158 | NCT00053157 | June 2002 | 19 February 2015 | Sargramostim in Reducing Graft-Versus-Host Disease in Patients Who Are Undergoing Donor Stem Cell Transplantation for Hematologic Cancer or Aplastic Anemia | Use Of Granulocyte Macrophage Colony Stimulating Factor (GM-CSF) To Mobilize Donor Peripheral Blood Stem Cells Along With GM-CSF Administration Post Allogeneic Transplant - A Pilot Study | Chronic Myeloproliferative Disorders;Graft Versus Host Disease;Leukemia;Lymphoma;Myelodysplastic Syndromes;Myelodysplastic/Myeloproliferative Neoplasms | Biological: sargramostim | Roswell Park Cancer Institute | National Cancer Institute (NCI) | Not recruiting | 5 Years | 60 Years | Both | 10 | N/A | United States |
| 159 | NCT00054236 | May 2002 | 19 February 2015 | Combination Chemotherapy Followed By Umbilical Cord Blood Transplantation in Treating Patients With Hematologic Cancer or Severe Aplastic Anemia | Pilot Study Of Multiple Umbilical Cord Blood Unit Transplantation Following Non-Myeloablative Conditioning In Patients With Hematologic Disorders Or Severe Aplastic Anemia | Chronic Myeloproliferative Disorders;Leukemia;Lymphoma;Multiple Myeloma and Plasma Cell Neoplasm;Myelodysplastic Syndromes;Myelodysplastic/Myeloproliferative Diseases | Biological: anti-thymocyte globulin;Biological: filgrastim;Drug: cyclophosphamide;Drug: fludarabine phosphate;Procedure: umbilical cord blood transplantation;Drug: methylprednisolone | Case Comprehensive Cancer Center | National Cancer Institute (NCI) | Not recruiting | N/A | N/A | Both | 55 | Phase 1 | United States |
| 160 | NCT00578903 | February 2002 | 19 October 2017 | Allogeneic Stem Cell Transplant for Patients With Severe Aplastic Anemia | Allogeneic Stem Cell Transplantation for Patients With Severe Aplastic Anemia, Using Matched Unrelated Donors and Mismatched Related Donors (SAA MUD) | Aplastic Anemia | Drug: Cytoxan;Drug: Campath;Radiation: Total Body Irradiation (TBI);Drug: FK-506;Drug: Methotrexate;Procedure: Stem cell infusion | Baylor College of Medicine | The Methodist Hospital System;Texas Children's Hospital;Center for Cell and Gene Therapy, Baylor College of Medicine | Not recruiting | N/A | 60 Years | All | 22 | Phase 2 | United States |
| No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
| 161 | NCT00053989 | January 29, 2002 | 17 September 2018 | Peripheral Stem Cell Transplant in Treating Patients With Hematologic Cancer or Aplastic Anemia | Non-Myeloablative Allogeneic Peripheral Blood Stem Cell Transplantation for Hematologic Malignancies and Aplastic Anemia | Chronic Myeloproliferative Disorders;Leukemia;Lymphoma;Multiple Myeloma and Plasma Cell Neoplasm;Myelodysplastic Syndromes;Myelodysplastic/Myeloproliferative Diseases | Biological: graft-versus-tumor induction therapy;Biological: sargramostim;Biological: therapeutic allogeneic lymphocytes;Drug: cyclophosphamide;Drug: fludarabine phosphate;Drug: methylprednisolone;Drug: mycophenolate mofetil;Drug: tacrolimus;Procedure: allogeneic bone marrow transplantation;Procedure: peripheral blood stem cell transplantation;Procedure: umbilical cord blood transplantation;Biological: anti-thymocyte globulin | Roswell Park Cancer Institute | Not recruiting | 5 Years | 75 Years | All | 41 | Phase 2 | United States | |
| 162 | NCT00590460 | July 2001 | 11 June 2018 | Antibody Conditioning Regimen For Allogeneic Donor Stem Cell Transplantation Of Patients With Fanconi Anemia | Cd45 (Yth-24 and Yth 54) and Cd52 (Campath-1H) Monoclonal Antibody Conditioning Regimen for Allogeneic Donor Stem Cell Transplantation of Patients With Fanconi Anemia | Fanconi Anemia;Severe Aplastic Anemia | Biological: CAMPATH-1H;Biological: Anti-CD45;Drug: Fludarabine;Procedure: Stem cell infusion | Baylor College of Medicine | Texas Children's Hospital;The Methodist Hospital System;Center for Cell and Gene Therapy, Baylor College of Medicine | Not recruiting | N/A | N/A | All | 5 | Phase 1/Phase 2 | United States |
| 163 | NCT00017654 | April 2001 | 19 February 2015 | Study of Allogeneic Bone Marrow and T-Cell Depleted, CD34+ Peripheral Blood Stem Cell Transplantation in Patients With Aplastic Anemia | Graft Versus Host Disease;Aplastic Anemia | Drug: anti-thymocyte globulin;Drug: cyclophosphamide;Drug: cyclosporine;Drug: methylprednisolone;Procedure: Allogeneic Bone Marrow Transplantation | Northwestern Memorial Hospital | Not recruiting | 15 Years | 55 Years | Both | 3 | N/A | United States | ||
| 164 | NCT01163942 | March 2001 | 13 April 2015 | Randomized Study In Severe Aplastic Anemia Patients Receiving Atg, Cyclosporin A, With Or Without G-CSF (SAA-G-CSF) | A RANDOMIZED CONTROLLED STUDY IN NEWLY DIAGNOSED SEVERE APLASTIC ANEMIA PATIENTS RECEIVING ANTITHYMOCYTE GLOBULIN (ATG), CYCLOSPORIN A, WITH OR WITHOUT G-CSF | Aplastic Anaemia | Drug: G-CSF;Drug: Early retreatment with ATG | European Group for Blood and Marrow Transplantation | CHUGAI sanofi-aventis | Not recruiting | N/A | N/A | Both | 205 | Phase 3 | Czech Republic;France;Germany;Greece;Italy;Netherlands;Sweden;Switzerland;United Kingdom |
| 165 | NCT00011830 | February 2001 | 19 February 2015 | Stem Cell Mobilization Potential in Patients With Aplastic Anemia in Remission | A Pilot Study of G-CSF Induced Stem Cell Mobilization Potential in Patients With Relapsed Severe Aplastic Anemia | Aplastic Anemia | Drug: G-CSF;Procedure: Apheresis | National Heart, Lung, and Blood Institute (NHLBI) | Not recruiting | N/A | N/A | Both | 20 | Phase 1 | United States | |
| No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
| 166 | NCT00427336 | December 2000 | 19 October 2017 | Purine Analog-Based Conditioning in Patients With Severe Aplastic Anemia | Purine Analog-Based Conditioning for Allogeneic Stem Cell Transplantation in Patients With Severe Aplastic Anemia | Aplastic Anemia | Drug: Fludarabine;Drug: Cyclophosphamide;Drug: Antithymocyte Globulin | M.D. Anderson Cancer Center | Not recruiting | N/A | 70 Years | All | 9 | N/A | United States | |
| 167 | NCT00005935 | June 2000 | 19 February 2015 | Mycophenolate Mofetil and Cyclosporine to Treat Relapsing Aplastic Anemia | A Randomized Trial for the Treatment of Relapsing Aplastic Anemia With Mycophenolate Mofetil (MMF) and Cyclosporine (CSA) | Aplastic Anemia | Drug: Mycophenolate mofetil;Drug: Cyclosporine | National Heart, Lung, and Blood Institute (NHLBI) | Not recruiting | N/A | N/A | Both | 130 | Phase 2 | United States | |
| 168 | NCT00006379 | June 2000 | 19 February 2015 | Non-Ablative Allo HSCT For Hematologic Malignancies or SAA | Purine-Analog-Containing Non-Myeloablative Allogeneic Stem Cell Transplantation for Treatment of Hematologic Malignancies and Severe Aplastic Anemia | Chronic Myeloproliferative Disorders;Leukemia;Lymphoma;Multiple Myeloma and Plasma Cell Neoplasm;Myelodysplastic Syndromes;Myelodysplastic/Myeloproliferative Diseases;Precancerous/Nonmalignant Condition;Small Intestine Cancer | Biological: anti-thymocyte globulin;Biological: graft-versus-tumor induction therapy;Drug: cyclophosphamide;Drug: fludarabine phosphate;Procedure: peripheral blood stem cell transplantation | Case Comprehensive Cancer Center | National Cancer Institute (NCI) | Not recruiting | N/A | 70 Years | Both | 58 | Phase 2 | United States |
| 169 | NCT01499147 | February 2000 | 16 December 2017 | Fludarabine Based Conditioning for Allogeneic Transplantation for Advanced Hematologic Malignancies | Fludarabine Based Conditioning for Allogeneic Transplantation for Advanced Hematologic Malignancies | Acute Myeloid Leukemia;Acute Leukemia;Chronic Myelogenous Leukemia;Malignant Lymphoma;Hodgkin's Disease;Multiple Myeloma;Lymphocytic Leukemia;Myeloproliferative Disorder;Polycythemia Vera;Myelofibrosis;Aplastic Anemia | Drug: fludarabine/busulfan;Drug: fludarabine/ melphalan;Drug: ATG | University of Illinois at Chicago | Not recruiting | 10 Years | 65 Years | All | 100 | N/A | United States | |
| 170 | NCT00001964 | December 2, 1999 | 4 November 2019 | Combination Therapy of Severe Aplastic Anemia | Treatment of Severe Aplastic Anemia With Combined Immunosuppression: Antithymocyte Globulin (ATG) and Cyclosporine A (CSA), and Mycophenolate Mofetil (MMF) | Severe Aplastic Anemia | Drug: Cyclosporine A;Drug: ATG;Drug: MMF | National Heart, Lung, and Blood Institute (NHLBI) | Not recruiting | 1 Year | 99 Years | All | 104 | Phase 2 | United States | |
| No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
| 171 | NCT00001962 | November 1999 | 19 October 2017 | A Study to Determine Whether Therapy With Daclizumab Will Benefit Patients With Bone Marrow Failure | A Pilot Study of Recombinant Humanized Anti-Interleukin (IL-2) Receptor Antibody (Daclizumab) in Patients With Moderate Aplastic Anemia, Pure Red Cell Aplasia, or Diamond Blackfan Anemia | Aplastic Anemia;Pure Red Cell Aplasia;Diamond Blackfan Anemia | Drug: Daclizumab | Neal Young, M.D. | Not recruiting | 2 Years | N/A | All | 100 | Phase 2 | United States | |
| 172 | NCT00004143 | September 1999 | 19 October 2017 | Allogeneic Mixed Chimerism Stem Cell Transplant Using Campath for Hemoglobinopathies & Bone Marrow Failure Syndromes | Allogeneic Mixed Chimerism Stem Cell Transplantation Utilizing In Vivo and In Vitro Campath for Hemoglobinopathies and Bone Marrow Failure Syndromes | Sickle Cell Anemia;Severe Aplastic Anemia;Paroxysmal Nocturnal Hemoglobinuria (PNH);Pure Red Cell Aplasia | Drug: Campath, Chemo and/or TBI Allo SCT | David Rizzieri, MD | Not recruiting | 18 Years | N/A | All | 2 | Phase 2 | United States | |
| 173 | NCT00636909 | July 1999 | 16 December 2017 | Nonmyeloablative Allo SCT for the Treatment of Hematologic Disorders | Nonmyeloablative Allogeneic Stem Cell Transplant for the Treatment of Hematologic Disorders | AML;ALL;CML Chronic Phase, Accelerated Phase, or Blast Crisis;CLL;MDS;RELAPSED NON-HODGKIN'S OR HODGKIN'S LYMPHOMA;APLASTIC ANEMIA;MULTIPLE MYELOMA;MYELOPROLIFERATIVE DISORDER (P Vera, CMML, ET) | Drug: Cyclophosphamide;Drug: fludarabine;Drug: cyclosporine;Drug: methotrexate;Biological: G-CSF | Beth Israel Deaconess Medical Center | Amgen | Not recruiting | N/A | 65 Years | All | 25 | Phase 2 | |
| 174 | NCT00003816 | October 19, 1998 | 30 September 2019 | Combination Chemotherapy and Donor Stem Cell Transplant in Treating Patients With Aplastic Anemia or Hematologic Cancer | Allogeneic Blood or Marrow Transplantation for Hematologic Malignancy and Aplastic Anemia | Chronic Myeloproliferative Disorders;Leukemia;Lymphoma;Myelodysplastic Syndromes;Myelodysplastic/Myeloproliferative Diseases;Nonmalignant Neoplasm;Unspecified Adult Solid Tumor, Protocol Specific;Unspecified Childhood Solid Tumor, Protocol Specific | Biological: anti-thymocyte globulin;Drug: busulfan;Drug: carboplatin;Drug: cyclophosphamide;Drug: etoposide;Drug: fludarabine phosphate;Drug: melphalan;Drug: thiotepa;Radiation: total-body irradiation | Roswell Park Cancer Institute | Not recruiting | 4 Years | 70 Years | All | 362 | Phase 2/Phase 3 | United States | |
| 175 | NCT00004474 | September 1998 | 11 June 2018 | Phase III Randomized Study of Cyclophosphamide With or Without Antithymocyte Globulin Before Bone Marrow Transplantation in Patients With Aplastic Anemia | Phase III Randomized Study of Cyclophosphamide With or Without Antithymocyte Globulin Before Bone Marrow Transplantation in Patients With Aplastic Anemia | Aplastic Anemia | Drug: Anti-thymocyte globulin;Drug: Cyclophosphamide;Procedure: Bone marrow transplantation | Roswell Park Cancer Institute | Not recruiting | N/A | 59 Years | All | 224 | Phase 3 | United States | |
| No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
| 176 | NCT00003336 | January 1998 | 19 February 2015 | Pilot Study Of Unrelated UCB Transplant for Non-Malignant Hematologic Conditions | A Pilot Study of Unrelated Umbilical Cord Blood Transplantation in Patients With Severe Aplastic Anemia, Inborn Errors in Metabolism, or Inherited Hematologic Stem Cell Disorders | Leukemia;Myelodysplastic Syndromes;Myelodysplastic/Myeloproliferative Diseases | Biological: anti-thymocyte globulin;Drug: busulfan;Drug: cyclophosphamide;Drug: melphalan;Drug: methylprednisolone;Procedure: bone marrow ablation with stem cell support;Procedure: umbilical cord blood transplantation;Radiation: radiation therapy | Case Comprehensive Cancer Center | National Cancer Institute (NCI) | Not recruiting | N/A | 55 Years | Both | 6 | Phase 2 | United States |
| 177 | NCT00001626 | June 2, 1997 | 7 October 2019 | Comparing Therapies for the Treatment of Severe Aplastic Anemia | A Randomized Trial of Antithymocyte Globulin and Cyclosporine Versus Cyclophosphamide and Cyclosporine in the Treatment of Severe Aplastic Anemia | Severe Aplastic Anemia (SAA) | Drug: antithymocyte globulin;Drug: cyclophosphamide;Drug: cyclosporine | National Heart, Lung, and Blood Institute (NHLBI) | Not recruiting | 15 Years | 110 Years | All | 33 | Phase 2 | United States | |
| 178 | NCT00005852 | June 1996 | 19 February 2015 | Bone Marrow Transplantation in Treating Patients With Severe Aplastic Anemia or Rejection of Previous Bone Marrow Transplant | Allogeneic Bone Marrow Transplantation for Marrow Failure States | Chronic Myeloproliferative Disorders;Graft Versus Host Disease;Leukemia;Lymphoma;Multiple Myeloma and Plasma Cell Neoplasm;Myelodysplastic Syndromes | Biological: anti-thymocyte globulin;Biological: filgrastim;Biological: muromonab-CD3;Drug: cyclophosphamide;Drug: cyclosporine;Drug: methylprednisolone;Procedure: allogeneic bone marrow transplantation | H. Lee Moffitt Cancer Center and Research Institute | National Cancer Institute (NCI) | Not recruiting | 15 Years | 55 Years | Both | Phase 2 | ||
| 179 | NCT00004464 | February 1996 | 28 January 2019 | Study of High Dose Cyclophosphamide in Patients With Severe Aplastic Anemia and Paroxysmal Nocturnal Hemoglobinuria | High Dose Cyclophosphamide for the Treatment of Severe Aplastic Anemia and Paroxysmal Nocturnal Hemoglobinuria | Aplastic Anemia;Paroxysmal Hemoglobinuria, Nocturnal | Drug: cyclophosphamide;Drug: filgrastim | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Not recruiting | N/A | 70 Years | All | 69 | Phase 2 | United States | |
| 180 | NCT00002718 | November 1995 | 4 January 2016 | T-cell Depleted Bone Marrow and G-CSF Stimulated Peripheral Stem Cell Transplantation From Related Donors in Treating Patients With Leukemia, Lymphoblastic Lymphoma, Myelodysplastic Syndrome, or Aplastic Anemia | A Phase II Trial of T-Cell Depleted Marrow Grafts Combined With Infusions of G-CSF Stimulated, CD34 Ceprate Stem Cell Column Selected, E-Rosette Depleted Peripheral Blood Progenitor Cells Derived From HLA Haplotype Matched Related Donors for Patients With Leukemia Lacking an HLA-Matched Related or Unrelated Donor | Leukemia;Lymphoma;Myelodysplastic Syndromes;Myelodysplastic/Myeloproliferative Neoplasms | Biological: anti-thymocyte globulin;Biological: filgrastim;Drug: cyclophosphamide;Drug: cytarabine;Drug: methylprednisolone;Drug: thiotepa;Procedure: in vitro-treated bone marrow transplantation;Procedure: in vitro-treated peripheral blood stem cell transplantation;Radiation: radiation therapy | Memorial Sloan Kettering Cancer Center | National Cancer Institute (NCI) | Not recruiting | N/A | 49 Years | Both | 31 | Phase 2 | United States |
| No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
| 181 | NCT00004323 | February 1995 | 19 February 2015 | Phase II Study of Bone Marrow Transplantation Using Related Donors in Patients With Aplastic Anemia | Aplastic Anemia | Drug: anti-thymocyte globulin;Drug: cyclophosphamide;Drug: cyclosporine;Drug: mesna;Drug: methotrexate;Drug: methylprednisolone | National Center for Research Resources (NCRR) | University of California, Los Angeles | Not recruiting | N/A | 55 Years | Both | 10 | Phase 2 | United States | |
| 182 | NCT00001398 | October 1993 | 19 February 2015 | Stem Cell Factor Medication for Aplastic Anemia | A Phase I/II Trial of Recombinant Methionyl Human Stem Cell Factor (r-metHuSCF) in Patients Diagnosed With Acquired Aplastic Anemia | Aplastic Anemia;Pancytopenia | Drug: Recombinant Methionyl Human Stem Cell Factor (r-metHuSCF) | National Heart, Lung, and Blood Institute (NHLBI) | Not recruiting | N/A | N/A | Both | 40 | Phase 1 | United States | |
| 183 | NCT00212407 | February 1993 | 12 November 2018 | New York Blood Center National Cord Blood Program | New York Blood Center National Cord Blood Program | Leukemia;Lymphoma;Genetic Disease;Severe Aplastic Anemia;Myelodysplasia | Biological: Umbilical Cord Blood Transplantation | New York Blood Center | Not recruiting | N/A | N/A | All | 4476 | Early Phase 1 | United States | |
| 184 | NCT00000597 | March 1982 | 19 February 2015 | Multi-Center Trial of Anti-Thymocyte Globulin in Treatment of Aplastic Anemia and Other Hematologic Disorders | Anemia, Aplastic;Hematologic Diseases;Pancytopenia;Blood Disease | Drug: antilymphocyte serum;Drug: nandrolone | National Heart, Lung, and Blood Institute (NHLBI) | Not recruiting | 18 Years | 75 Years | Both | Phase 3 |